Propanc Biopharma (PPCBD) 10-K 28 Sep 22 2022 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Jun. 30, 2022	Sep. 26, 2022	Dec. 31, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--06-30
Entity File Number	000-54878
Entity Registrant Name	PROPANC BIOPHARMA, INC.
Entity Central Index Key	0001517681
Entity Tax Identification Number	33-0662986
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	302
Entity Address, Address Line Two	6 Butler Street
Entity Address, City or Town	Camberwell, VIC
Entity Address, Country	AU
Entity Address, Postal Zip Code	3124
City Area Code	61 03
Local Phone Number	9882 0780
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 1,519,637
Entity Common Stock, Shares Outstanding		677,177,717
Auditor Firm ID	106
Auditor Name	SALBERG & COMPANY, P.A
Auditor Location	Boca Raton, Florida

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2022	Jun. 30, 2021
CURRENT ASSETS:
Cash	$ 4,067	$ 2,255
GST tax receivable	2,342	4,341
Prepaid expenses and other current assets	8,621
TOTAL CURRENT ASSETS	15,030	6,596
Security deposit - related party	2,075	2,250
Operating lease right-of-use assets, net - related party	62,523
Property and equipment, net	2,023	4,255
TOTAL ASSETS	81,651	13,101
CURRENT LIABILITIES:
Accounts payable	943,023	1,002,335
Accrued expenses and other payables	466,115	892,151
Convertible notes and related accrued interest, net of discounts and premiums	984,260	624,583
Operating lease liability - related party, current portion	20,605
Embedded conversion option liabilities	151,262	54,220
Due to former director - related party	30,746	33,347
Loan from former director - related party	51,171	55,500
Employee benefit liability	415,799	418,538
TOTAL CURRENT LIABILITIES	3,062,981	3,080,674
NON-CURRENT LIABILITIES:
Operating lease liability - long-term portion - related party	42,319
TOTAL NON-CURRENT LIABILITIES	42,319
TOTAL LIABILITIES	3,105,300	3,080,674
Commitments and Contingencies (See Note 9)
STOCKHOLDERS’ DEFICIT:
Common stock, $0.001 par value; 3,000,000,000 shares authorized; 220,350,921 and 14,055,393 shares issued and outstanding as of June 30, 2022 and 2021, respectively	220,351	14,056
Common stock issuable (19,597,024 and 59 shares as of June 30, 2022 and 2021, respectively)	19,597
Additional paid-in capital	57,124,982	54,074,110
Subscription receivable	(23,758)
Accumulated other comprehensive income	1,234,549	1,085,204
Accumulated deficit	(61,557,893)	(58,199,466)
Treasury stock (1 share)	(46,477)	(46,477)
TOTAL STOCKHOLDERS’ DEFICIT	(3,023,649)	(3,067,573)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	81,651	13,101
Series A Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT:
Preferred stock value	5,000	5,000
Series B Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT:
Preferred stock value

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2022	Jun. 30, 2021
Preferred stock, shares authorized	1,500,005	1,500,005
Preferred stock, par value	$ 0.01	$ 0.01
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	3,000,000,000	3,000,000,000
Common stock, shares issued	220,350,921	14,055,393
Common stock, shares outstanding	220,350,921	14,055,393
Common stock, shares issuable	19,597,024	59
Treasury stock, shares	1	1
Series A Preferred Stock [Member]
Preferred stock, shares authorized	500,000	500,000
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares issued	500,000	500,000
Preferred stock, shares outstanding	500,000	500,000
Series B Preferred Stock [Member]
Preferred stock, shares authorized	5	5
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares issued	1	1
Preferred stock, shares outstanding	1	1

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
REVENUE
Revenue
OPERATING EXPENSES
Administration expenses	1,706,452	1,553,075
Occupancy expenses – related party	28,366	28,112
Research and development	256,052	230,956
TOTAL OPERATING EXPENSES	1,990,870	1,812,143
LOSS FROM OPERATIONS	(1,990,870)	(1,812,143)
OTHER INCOME (EXPENSE)
Interest expense	(568,798)	(449,457)
Interest income	5,613	1
Change in fair value of derivative liabilities	(99,111)	(8,186)
Gain from settlement of debt, net		49,319
Gain (loss) on extinguishment of debt, net	(17,503)	50,607
Foreign currency transaction gain (loss)	(42,395)	30,497
TOTAL OTHER EXPENSE, NET	(722,194)	(327,219)
LOSS BEFORE TAXES	(2,713,064)	(2,139,362)
Tax benefit	54,977	113,415
NET LOSS	(2,658,087)	(2,025,947)
Deemed Dividend	(700,340)	(391,749)
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS	$ (3,358,427)	$ (2,417,696)
BASIC AND DILUTED NET LOSS PER SHARE AVAILABLE TO COMMON STOCKHOLDERS	$ (0.05)	$ (0.80)
BASIC AND DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING	68,218,701	3,032,612
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS	$ (3,358,427)	$ (2,417,696)
OTHER COMPREHENSIVE INCOME (LOSS)
Unrealized foreign currency translation gain (loss)	149,345	(182,467)
TOTAL OTHER COMPREHENSIVE INCOME (LOSS)	149,345	(182,467)
TOTAL COMPREHENSIVE LOSS	$ (3,209,082)	$ (2,600,163)

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficit - USD ($)	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Common Stock Issuable [Member]	Additional Paid-in Capital [Member]	Subscription Receivable [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Treasury Stock [Member]	Total
Beginning balance, value at Jun. 30, 2020	$ 5,000		$ 258		$ 50,913,893		$ (55,781,770)	$ 1,267,671	$ (46,477)	$ (3,641,425)
Beginning balance, shares at Jun. 30, 2020	500,000	1	258,120
Issuance of common stock for conversion of convertible debt and accrued interest			$ 8,787		1,230,288					1,239,075
Issuance of common stock for conversion of convertible debt and accrued interest, shares			8,786,113
Reversal of common stock issuable due to cancellation of conversions of convertible debt and accrued interest			$ (24)		(19,992)					(20,016)
Reversal of common stock issuable due to cancellation of conversions of convertible debt and accrued interest, shares			(24,427)
Issuance of common stock for services			$ 806		124,766					125,572
Issuance of common stock for services, shares			805,646
Issuance of common stock for exercise of warrants			$ 29		776,015					776,044
Issuance of common stock for exercise of warrants, shares			29,820
Issuance of common stock for cashless exercise of warrants			$ 4,200		(4,200)
Issuance of common stock for cashless exercise of warrants, shares			4,199,979
Reclassification of put premium upon debt conversion					590,504					590,504
Reversal of put premium upon cancellation of conversions of convertible debt					(11,785)					(11,785)
Stock based compensation in connection with stock option grants					82,872					82,872
Vested restricted stock units
Vested restricted stock units, shares				59
Fractional difference due to the reverse stock-split
Fractional difference due to the reverse stock-split, shares			142
Foreign currency translation gain								(182,467)		(182,467)
Deemed dividend upon alternate cashless exercise of warrants					391,749		(391,749)
Net loss							(2,025,947)			(2,025,947)
Issuance of common stock for cash, shares			29,820
Ending balance, value at Jun. 30, 2021	$ 5,000		$ 14,056		54,074,110		(58,199,466)	1,085,204	(46,477)	(3,067,573)
Ending balance, shares at Jun. 30, 2021	500,000	1	14,055,393	59
Issuance of common stock for exercise of warrants			$ 15		624,986					625,001
Issuance of common stock for exercise of warrants, shares			15,625
Reclassification of put premium upon debt conversion					335,677					335,677
Stock based compensation in connection with stock option grants					72,513					72,513
Foreign currency translation gain								149,345		149,345
Deemed dividend upon alternate cashless exercise of warrants					700,340		(700,340)
Net loss							(2,658,087)			(2,658,087)
Issuance of common stock for cash			$ 25,663		97,380	(23,758)				$ 99,285
Issuance of common stock for cash, shares			25,663,288							56,799,716
Issuance of common stock for offering cost			$ 1,000		(1,000)
Issuance of common stock for offering cost, shares			1,000,000
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest			$ 96,960	$ 7,326	552,839					657,125
Issuance of common stock for conversion of convertible debt, conversion fee and accrued interest, shares			96,959,620	7,326,007
Issuance of common stock for services and accrued expenses			$ 25,857	$ 12,271	724,937					763,065
Issuance of common stock for services and accrued expenses, shares			25,857,279	12,270,958
Issuance of common stock for alternate cashless exercise of warrants			$ 56,800		(56,800)
Issuance of common stock for alternate cashless exercise of warrants, shares			56,799,716
Ending balance, value at Jun. 30, 2022	$ 5,000		$ 220,351	$ 19,597	$ 57,124,982	$ (23,758)	$ (61,557,893)	$ 1,234,549	$ (46,477)	$ (3,023,649)
Ending balance, shares at Jun. 30, 2022	500,000	1	220,350,921	19,597,024

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,658,087)	$ (2,025,947)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Issuance and amortization of common stock for services	314,626	125,572
Foreign currency transaction (gain) loss	42,395	(30,497)
Depreciation expense	1,993	1,993
Amortization of debt discounts	47,971	136,527
Change in fair value of derivative liabilities	99,111	8,186
(Gain) loss on extinguishment of debt, net	17,503	(50,607)
Gain from settlement of debt, net		(49,319)
Stock option and restricted stock expense	72,513	82,872
Non-cash interest expense	2,250	16,500
Amortization of right-of-use assets	3,678
Accretion of put premium	452,308	200,410
Changes in Assets and Liabilities:
GST receivable	1,660	(2,147)
Prepaid expenses and other assets	(8,620)
Accounts payable	18,870	178,311
Deferred rent		(3,695)
Employee benefit liability	29,907	33,134
Accrued expenses and other payables	65,017	152,861
Accrued interest	63,878	80,582
Operating lease liability	(3,277)
NET CASH USED IN OPERATING ACTIVITIES	(1,436,304)	(1,145,264)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from convertible promissory notes, net of original issue discounts and issue costs	766,500	325,000
Repayments of convertible promissory notes		(43,000)
Proceeds from the sale of common stock	99,285
Proceeds from the exercise of warrants	625,001	776,044
NET CASH PROVIDED BY FINANCING ACTIVITIES	1,490,786	1,058,044
Effect of exchange rate changes on cash	(52,670)	22,468
NET INCREASE (DECREASE) IN CASH	1,812	(64,752)
CASH AT BEGINNING OF YEAR	2,255	67,007
CASH AT END OF YEAR	4,067	2,255
Supplemental Disclosure of Cash Flow Information
Interest	2,392	13,621
Income Tax
Supplemental Disclosure of Non-Cash Investing and Financing Activities
Common stock issued for offering cost applied against proceeds received	20,000
Subscription receivable	23,758
Reduction of put premium related to conversions of convertible notes	335,677	590,504
Conversion of convertible notes and accrued interest to common stock	635,303	1,142,205
Discounts related to derivative liability
Operating lease right-of-use asset and operating lease liability recorded pursuant to ASC 842	66,201
Reversal of common stock issuable and put premium due to cancellation of conversions of convertible debt and accrued interest		31,801
Accounts payable reclass to convertible notes		25,000
Common stock issued for accrued services	448,440
Deemed dividend upon alternate cashless exercise of warrants	$ 700,340	$ 391,749

NATURE OF OPERATIONS AND SUMMAR

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES	12 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES	NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES Nature of Operations Propanc Biopharma, Inc. (the “Company,” “we,” “us” or “our”) was originally incorporated in Melbourne, Victoria Australia on October 15, 2007 as Propanc PTY LTD, and continues to be based in Camberwell, Victoria Australia. Since its inception, substantially all of the operations of the Company have been focused on the development of new cancer treatments targeting high-risk patients, particularly cancer survivors, who need a follow-up, non-toxic, long-term therapy designed to prevent the cancer from returning and spreading. The Company anticipates establishing global markets for its technologies. Our lead product candidate, which we refer to as PRP, is an enhanced pro-enzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. It is currently in the preclinical phase of development. On November 23, 2010, the Company was incorporated in the state of Delaware as Propanc Health Group Corporation. In January 2011, to reorganize the Company, we acquired all of the outstanding shares of Propanc PTY LTD on a one-for-one basis making it a wholly-owned subsidiary of the Company. On July 22, 2016, the Company formed a wholly owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose of submitting an orphan drug application to the European Medicines Agency as a small and medium-sized enterprise. As of June 30, 2022, there has been no activity within this entity. Effective April 20, 2017, the Company changed its name to “Propanc Biopharma, Inc.” to better reflect the Company’s stage of operations and development. In July 2020, a world first patent was granted in Australia for the cancer treatment method patent family. Presently, there are 43 granted, allowed, or accepted patents and 22 patents filed, or under examination in key global jurisdictions relating to the use of proenzymes against solid tumors, covering the lead product candidate PRP. The Company hopes to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer by filing additional patent applications as it advances its lead product candidate, PRP, through various stages of development. On November 17, 2020, the Company effected a one-for-one thousand On May 18, 2022, the board of directors of the Company approved and authorized, and the holders of a majority in interest of the Company’s voting capital stock approved by written consent, in accordance with Section 228 of the Delaware General Corporation Law, for the Company to file a Certificate of Amendment to its Certificate of Incorporation (the “Certificate”) with the Secretary of State of the State of Delaware, which increased the Company’s authorized capital stock. The Certificate increased the number of authorized shares of the Company’s common stock, par value $ 0.001 1,000,000,000 3,000,000,000 1,500,005 3,001,500,005 Principles of Consolidation The consolidated financial statements include the accounts of Propanc Biopharma, Inc., the parent entity, and its wholly-owned subsidiary, Propanc PTY LTD. All inter-company balances and transactions have been eliminated in consolidation. Propanc (UK) Limited was an inactive wholly-owned subsidiary through June 30, 2022. Use of Estimates The preparation of financial statements in conformity with the accounting principles generally accepted in the United States of America (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives for depreciation, valuation of the operating lease liability and related right-of-use asset, valuation of derivatives, valuation of beneficial conversion features on convertible debt, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 Foreign Currency Translation and Other Comprehensive Income (Loss) The Company’s wholly owned subsidiary’s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into the Company’s reporting currency which is the United States dollar ($) and/or (USD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “Accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency transactions are included in the statements of operations and comprehensive income (loss) as a component of other comprehensive income (loss). There have been no significant fluctuations in the exchange rate for the conversion of Australian dollars to USD after the balance sheet date. Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses). Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the consolidated balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency included in the consolidated results of operations as incurred. Effective fiscal year 2021, the parent company determined that the intercompany loans will not be repaid in the foreseeable future and thus, per ASC 830-20-35-3, gains and losses from measuring the intercompany balances are recorded within cumulative translation adjustment, a component of accumulated other comprehensive income (loss). Prior to July 1, 2020, the Company recorded the foreign currency transaction gains and losses from measuring the intercompany balances as a component of other income (expenses) titled foreign currency transaction gain (loss). For the year ended June 30, 2022 and 2021, the Company recognized an exchange gain (loss) of approximately $ 1,289,000 $1,005,000 As of June 30, 2022 and 2021, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: SCHEDULE OF TRANSLATION EXCHANGE RATES June 30, 2022 June 30, 2021 Exchange rate on balance sheet dates USD : AUD exchange rate 0.6915 0.7500 Average exchange rate for the period USD : AUD exchange rate 0.7253 0.7473 Change in Accumulated Other Comprehensive Income (Loss) by component during the years ended June 30, 2022 and 2021 were as follows: SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS Foreign Beginning balance, June 30, 2020 $ 1,267,671 Foreign currency translation gain 182,467 Balance, June 30, 2021 1,085,204 Foreign currency translation gain 149,345 Ending balance, June 30, 2022 $ 1,234,549 Fair Value of Financial Instruments and Fair Value Measurements The Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and cash equivalents, receivables, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current interest rates available for debt with similar terms and maturities are substantially the same. The Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. Also see Note 12 - Derivative Financial Instruments and Fair Value Measurements. Cash and Cash Equivalents Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts, as applicable, are reflected as a current liability on the balance sheets. There were no Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method. The depreciable amount is the cost less its residual value. The estimated useful lives are as follows: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVE Machinery and equipment - 5 Furniture - 7 Patents Patents are stated at cost and amortized on a straight-line basis over the estimated future periods if and once the patent has been granted by a regulatory agency. However, the Company will expense any patent costs as long as we are in the startup stage. Accordingly, as the Company’s products are not currently approved for market, all patent costs incurred from 2013 through June 30, 2022 were expensed immediately. This practice of expensing patent costs immediately ends when a product receives market authorization from a government regulatory agency. Impairment of Long-Lived Assets In accordance with ASC 360-10, “Long-lived assets,” which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable. Employee Benefit/Liability Liabilities arising in respect of wages and salaries, accumulated annual leave, accumulated long service leave and any other employee benefits expected to be settled within twelve months of the reporting date are measured based on the employee’s remuneration rates applicable at the reporting date. All other employee benefit liabilities are measured at the present value of the estimated future cash outflow to be made in respect of services provided by employees up to the reporting date. All employee liabilities are owed within the next twelve months. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 Australian Goods and Services Tax (“GST”) Revenues, expenses and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office. Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows. As of June 30, 2022 and 2021, the Company was owed $ 2,342 4,341 Derivative Instruments ASC Topic 815, Derivatives and Hedging Convertible Notes With Variable Conversion Options The Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into common shares at a fixed discount to the price of the common stock at or around the time of conversion. The Company treats these convertible notes as stock settled debt under ASC 480, “ Distinguishing Liabilities from Equity Income Taxes The Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the United States Internal Revenue Service, respectively. The Company follows ASC 740 “ Accounting for Income Taxes The Company follows ASC 740, Sections 25 through 60, “ Accounting for Uncertainty in Income Taxes Research and Development Costs and Tax Credits In accordance with ASC 730-10, “Research and Development-Overall,” 256,052 230,956 The Company may apply for research and development tax concessions with the Australian Taxation Office on an annual basis. Although the amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income, then the Company can receive the credit which reduces its income tax liability. If the Company has net losses, then the Company may still receive a cash payment for the credit, however, the Company’s net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as tax benefit, in operations, upon receipt. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 During each of the fiscal years ended June 30, 2022 and 2021, the Company applied for, and received from the Australian Taxation Office, a research and development tax credit in the amount of $ 54,977 113,415 Stock Based Compensation The Company records stock-based compensation in accordance with ASC 718, “ Stock Compensation The Company adopted ASU 2018-07 and accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period. The Company used the modified prospective method of adoption. Revenue Recognition The Company applies ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures. Subject to these criteria, the Company intends to recognize revenue relating to royalties on product sales in the period in which the sale occurs and the royalty term has begun. Legal Expenses All legal costs for litigation are charged to expense as incurred. Leases The Company follows ASC Topic 842, Leases (Topic 842) and applies the package of practical expedients, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 month or less. Operating lease right of use assets (“ROU”) represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses. Basic and Diluted Net Loss Per Common Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. Each holder of the notes has agreed to a 4.99 9.99 SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE June 30, 2022 June 30, 2021 Stock Options 59 59 Stock Warrants 105,420 121,329 Unvested restricted stock 59 59 Convertible Debt 127,062,326 12,416,972 Total 127,167,864 12,538,419 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 Recent Accounting Pronouncements We have reviewed the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. We have carefully considered the new pronouncements that alter previous generally accepted accounting principles and do not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term with the exception of those disclosed below. The applicability of any standard is subject to the formal review of the Company’s financial management. In August 2020, the FASB issued ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40)”. This ASU reduces the number of accounting models for convertible debt instruments and convertible preferred stock as well as amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. In addition, this ASU improves and amends the related EPS guidance. This standard is effective for us on July 1, 2024, including interim periods within those fiscal years. Adoption is either a modified retrospective method or a fully retrospective method of transition. The Company is currently assessing the impact of the new guidance will have on our consolidated financial statements.

GOING CONCERN

GOING CONCERN	12 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 2 – GOING CONCERN The accompanying consolidated financial statements have been prepared in conformity with US GAAP, which contemplate continuation of the Company as a going concern. For the fiscal year ended June 30, 2022, the Company had no revenues, had a net loss of $ 2,658,087 1,436,304 3,047,951 3,023,649 61,557,893 The consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty. Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to fulfill its development activities, acceptance of the Company’s patent applications, obtaining additional sources of suitable and adequate financing and ultimately achieving a level of sales adequate to support the Company’s cost structure and business plan. The Company’s ability to continue as a going concern is also dependent on its ability to further develop and execute on its business plan. However, there can be no assurances that any or all of these endeavors will be successful. In March 2020, the outbreak of COVID-19 (coronavirus) caused by a novel strain of the coronavirus was recognized as a pandemic by the World Health Organization, and the outbreak has become increasingly widespread in the United States, Europe and Australia, including in each of the areas in which the Company operates. The COVID-19 (coronavirus) outbreak has had a notable impact on general economic conditions, including but not limited to the temporary closures of many businesses, “shelter in place” and other governmental regulations, reduced business and consumer spending due to both job losses, reduced investing activity and M&A transactions, among many other effects attributable to the COVID-19 (coronavirus), and there continue to be many unknowns. While to date the Company has not been required to stop operating, management is evaluating its use of its office space, virtual meetings and the like. The Company continues to monitor the impact of the COVID-19 (coronavirus) outbreak closely. The extent to which the COVID-19 (coronavirus) outbreak will impact our operations, ability to obtain financing or future financial results is uncertain.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 3 – PROPERTY AND EQUIPMENT Property and equipment consist of the following as of June 30: SCHEDULE OF PROPERTY PLANT AND EQUIPMENT 2022 2021 Office equipment at cost $ 28,623 $ 28,623 Less: Accumulated depreciation (26,600 ) (24,368 ) Total property, plant, and equipment $ 2,023 $ 4,255 Depreciation expense for the years ended June 30, 2022 and 2021 were $ 1,993 1,993 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021

DUE TO FORMER DIRECTOR - RELATE

DUE TO FORMER DIRECTOR - RELATED PARTY	12 Months Ended
	Jun. 30, 2022
Due To Former Director - Related Party
DUE TO FORMER DIRECTOR - RELATED PARTY	NOTE 4 – DUE TO FORMER DIRECTOR - RELATED PARTY Due to former director - related party represents unsecured advances made primarily by a former director for operating expenses on behalf of the Company such as intellectual property and formation expenses. The expenses were paid for on behalf of the Company and are due upon demand. The Company is currently not being charged interest under these advances. The total amount owed to the former director at June 30, 2022 and 2021 is $ 30,746 33,347

LOANS AND NOTES PAYABLE

LOANS AND NOTES PAYABLE	12 Months Ended
	Jun. 30, 2022
Loans And Notes Payable
LOANS AND NOTES PAYABLE	NOTE 5 – LOANS AND NOTES PAYABLE Loan from Former Director - Related Party Loan from the Company’s former director at June 30, 2022 and 2021 were $ 51,171 55,500

CONVERTIBLE NOTES

CONVERTIBLE NOTES	12 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
CONVERTIBLE NOTES	NOTE 6 – CONVERTIBLE NOTES The Company’s convertible notes outstanding at June 30, 2022 and 2021 were as follows: SCHEDULE OF CONVERTIBLE NOTES June 30, 2022 June 30, 2021 Convertible notes and debenture $ 644,980 $ 400,128 Unamortized discounts (31,669 ) (6,139 ) Accrued interest 57,822 34,098 Premium, net 313,127 196,496 Convertible notes, net $ 984,260 $ 624,583 Eagle Equities Financing Agreements August 29, 2018 Securities Purchase Agreement Effective August 29, 2018, the Company entered into a securities purchase agreement with Eagle Equities, pursuant to which Eagle Equities purchased a convertible promissory note (the “August 2018 Eagle Note”) from the Company in the aggregate principal amount of $ 105,000 August 29, 2019 8 24 December 24, 2018 Securities Purchase Agreement Effective December 24, 2018, the Company entered into a securities purchase agreement with Eagle Equities, pursuant to which Eagle Equities purchased a convertible promissory note (the “December 2018 Eagle Note”) from the Company in the aggregate principal amount of $ 126,000 6,000 December 24, 2019 8 24 24 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 Eagle Equities had the option to convert all or any amount of the principal amount of the notes issued to Eagle Equities above, at any time, for shares of the Company’s common stock at a price ranging from 60 61 50 51 10 4.99 The above notes issued to Eagle Equities were treated as stock settled debt under ASC 480 and accordingly, the Company recorded a total of $ 357,688 133,557 There were $ 0 Convertible Note Issued with Consulting Agreement August 10, 2017 Consulting Agreement On August 10, 2017, the Company entered into a consulting agreement, retroactive to May 16, 2017, with a certain consultant, pursuant to which the consultant agreed to provide certain consulting and business advisory services in exchange for a $ 310,000 August 10, 2017 10 750 65 ten August 10, 2019 155,000 155,000 18 578,212 140,000 10,764 161,000 19,418 9,000 500 5,248 8,500 22,168 On March 15, 2021, the Company entered into a Settlement and Mutual Release Agreement (the “Settlement Agreement”) with the consultant whereby both parties agreed to settle all claims and liabilities under the August 10, 2017 Convertible note for a total of $ 100,000 56,762 8,500 23,262 25,000 43,238 The total principal and accrued interest outstanding after adjustment due to the above mentioned March 15, 2021 settlement agreement under the August 10, 2017 Convertible Note was $ 80,000 3,738 20,000 79,000 10,185 1,000 8,000 GS Capital Financing Agreements January 22, 2020 GS Capital Securities Purchase Agreements Effective January 22, 2020, the Company entered into a securities purchase agreement with GS Capital, pursuant to which GS Capital purchased a convertible promissory note (the “January 22, 2020 GS Note”) from the Company in the aggregate principal amount of $ 58,000 3,500 2,500 52,000 January 22, 2021 10 40 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 Additionally, GS Capital had the option to convert all or any amount of the principal face amount of the January 22, 2020 GS Capital Note at any time from the date of issuance and ending on the later of the maturity date or the date the Default Amount was paid if an event of default occurs, which is an amount between 112 130 24 The note issued to GS capital above was treated as stock settled debt under ASC 480 and accordingly the Company recorded $ 38,667 38,667 The total remaining principal outstanding and accrued interest under the above GS Capital financing agreements was $ 0 58,000 8,508 Power Up Lending Group Financing Agreements January 7, 2020 Power Up Lending Group Securities Purchase Agreement Effective January 7, 2020, the Company entered into a securities purchase agreement with Power Up Lending Group Ltd. (“Power Up”), pursuant to which Power Up purchased a convertible promissory note (the “January 7, 2020 Power Up Note”) from the Company in the aggregate principal amount of $ 75,000 72,000 2,500 500 January 7, 2021 8 March 12, 2020 Power Up Lending Group Securities Purchase Agreement Effective March 12, 2020, the Company entered into a securities purchase agreement with Power Up Lending Group Ltd. (“Power Up”), pursuant to which Power Up purchased a convertible promissory note (the “March 12, 2020 Power Up Note”) from the Company in the aggregate principal amount of $ 43,000 40,000 2,500 500 March 12, 2021 8 All the notes issued above to Power Up contained certain events of default, upon which principal and accrued interest would become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal would accrue at a default interest rate of 22 Additionally, Power Up had the option to convert all or any amount of the principal face amount of the notes issued to Power Up, starting on certain dates as defined in the note agreements and ending on the later of the maturity date or the date the Default Amount is paid if an event of default occurs, which was an amount equal to 150 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 The conversion price for the above Power Up notes was $3,050, subject to certain Market Price (as defined below) adjustment. If the Market Price was greater than or equal to $5,000, the conversion price was to be the greater of 65 ten 4.99 422,557 The total principal amount outstanding under the above Power Up financing agreement, specifically the January 7, 2020 and March 12, 2020 Power Up Notes, was $ 0 0 43,000 1,816 no Auctus Fund Financing Agreements August 30, 2019 Securities Purchase Agreement Effective August 30, 2019, the Company entered into a securities purchase agreement with Auctus Fund, LLC (“Auctus”), pursuant to which Auctus purchased a convertible promissory note (the “August 30, 2019 Auctus Note”) from the Company in the aggregate principal amount of $ 550,000 550,000 5,000 40,000 505,000 August 30, 2020 10 366,667 24 Additionally, Auctus had the option to convert all or any amount of the principal face amount and accrued interest of the August 30, 2019 Auctus Note, at any time following the issue date and ending on the later of the maturity date or the date of payment of the Default Amount if an event of default occurs, which was an amount equal to 125 15,000 24 Upon the holder’s election to convert accrued interest, default interest or any penalty amounts as stipulated, the Company may elect to pay those amounts in cash. The note may also be prepaid by the Company at any time between the date of issuance and August 13, 2020 at 135% multiplied by the sum of (a) the then outstanding principal amount plus (b) accrued and unpaid interest plus (c) default interests, if any. The conversion price for the August 30, 2019 Auctus Note was a Variable Conversion Price, being 60 4.99 In connection with the issuance of the August 2019 Auctus Note, the Company issued common stock purchase warrants to Auctus to purchase 450 2,250 300 3,330 225 4,500 4.99 375,905 In connection with the Purchase Agreement, the Company and the Purchaser entered into a Registration Rights Agreement (the “Registration Rights Agreement”). Pursuant to the Registration Rights Agreement, the Company agreed to register the shares of Common Stock underlying the Securities in a Registration Statement with the SEC as well as the Commitment Shares (as defined herein). The Registration Rights Agreement contains customary representations, warranties, agreements and indemnification rights and obligations of the parties. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 The Note was subject to customary default provisions and also includes a cross-default provision which provides that a breach or default by the Borrower of any covenant or other term or condition contained in any of the Other Agreements (as defined therein), after the passage of all applicable notice and cure or grace periods, shall, at the option of the Holder, be considered a default under this Note and the Other Agreements. Upon occurrence of any such event, the Holder was entitled (but in no event required) to apply all rights and remedies of the Holder under the terms of this Note and the Other Agreements by reason of a default under said Other Agreements or the Note. The August 30, 2019 Auctus Note contained certain events of default, upon which principal and accrued interest were to become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 24 The total principal amount outstanding under the above Auctus financing agreement, specifically the August 30, 2019 Auctus Note, was $ 358,965 486 191,035 43,176 127,356 The total principal amount outstanding under the above Auctus financing agreement, specifically the August 30, 2019 Auctus Note, was $ 32,848 0 326,117 39,536 217,411 The total principal amount outstanding under the above Auctus financing agreement, specifically the August 30, 2019 Auctus Note, was $ 0 0 32,848 716 21,899 no Crown Bridge Securities Purchase Agreements Effective October 3, 2019, the Company entered into a securities purchase agreement with Crown Bridge Partners, pursuant to which Crown Bridge purchased a convertible promissory note (the “October 3, 2019 Crown Bridge Note”) from the Company in the aggregate principal amount of $ 108,000 3,000 5,000 100,000 October 3, 2019 15 Additionally, Crown Bridge has the option to convert all or any amount of the principal face amount of the October 3, 2019 Crown Bridge Note at any time from the date of issuance and ending on the later of the maturity date or the date the Default Amount is paid if an event of default occurs, which is an amount between 110 150 The conversion price for the October 3, 2019 Crown Bridge Note shall be equal to a 40% discount of the lowest closing bid price (“Lowest Trading Price”) of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion, including the day upon which a Notice of Conversion is received. Notwithstanding the foregoing, Crown Bridge shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Crown Bridge and its affiliates, exceeds 4.99 9.99 72,000 The October 3, 2019 Crown Bridge Note contain certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 15 The total principal amount outstanding under the above Crown Bridge financing agreement was $ 65,280 7,232 42,720 28,480 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 There were 15,000 st 9,600 6,400 16,000 The total principal amount outstanding under the above Crown Bridge financing agreement was $ 65,280 16,138 65,280 25,930 GW Holdings Securities Purchase Agreements October 1, 2019 Securities Purchase Agreement Effective October 1, 2019, the Company entered into a securities purchase agreement with GW Holdings, pursuant to which GW Holdings purchased a convertible promissory note (the “October 1, 2019 GW Note”) from the Company in the aggregate principal amount of $ 131,000 6,000 125,000 October 1, 2020 8 December 10, 2020 Securities Purchase Agreement Effective December 10, 2020, the Company entered into a securities purchase agreement with GW Holdings, pursuant to which GW Holdings purchased a convertible promissory note (the “December 10, 2020 GW Note”) from the Company in the aggregate principal amount of $ 131,000 6,000 125,000 December 10, 2021 8 The above notes issued to GW Holdings contain certain events of default, upon which principal and accrued interest were to become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 24 Additionally, GW Holdings had the option to convert all or any amount of the principal face amount of the notes issued to GW Holdings at any time from the date of issuance and ending on the later of the maturity date or the date the Default Amount is paid if an event of default occurs, which is an amount between 110 150 The conversion price for the above GW Holdings notes was equal to a 40% discount of the lowest closing bid price (“Lowest Trading Price”) of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion, including the day upon which a Notice of Conversion was received. Notwithstanding the foregoing, GW Holdings shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by GW Holdings and its affiliates, exceeds 4.99 9.99 These notes were treated as stock settled debt under ASC 480 and accordingly the Company recorded a total of $ 174,666 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 The total principal amount outstanding under the above October 1, 2019 GW Holdings financing agreement was $ 30,000 1,776 101,000 5,082 0 30,000 3,877 67,333 20,000 The total principal amount outstanding under the above December 10, 2020 GW Holdings financing agreement, was $ 90,000 4,636 41,000 1,084 27,333 The total principal amount outstanding and accrued interest under the above December 10, 2020 GW Holdings financing agreement, was $ 0 90,000 7,885 4,000 60,000 Ader Alef Securities Purchase Agreements Effective January 13, 2020, the Company entered into a securities purchase agreement with Ader Alef, pursuant to which Ader Alef purchased a convertible promissory note (the “January 13, 2020 Ader Alef Note”) from the Company in the aggregate principal amount of $ 110,250 5,250 5,000 100,000 January 13, 2020 8 Additionally, Ader Alef had the option to convert all or any amount of the principal face amount of the January 13, 2020 Ader Alef Note at any time from the date of issuance and ending on the later of the maturity date or the date the Default Amount was paid if an event of default occurs, which was an amount between 120 150 The conversion price for the January 13, 2020 Ader Alef Note during the first 6 months the January 13, 2020 Ader Alef Note was fixed at $2.50 and thereafter would be equal to a 35 4.99 9.99 59,365 The January 13, 2020 Ader Alef Note contained certain events of default, upon which principal and accrued interest would become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal would accrue at a default interest rate of 24 The total principal amount outstanding under the above Ader Alef financing agreement was $ 110,250 4,073 0 110,250 7,493 59,365 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 LG Capital Securities Purchase Agreements Effective February 19, 2020, the Company entered into a securities purchase agreement with LG Capital Funding, LLC (“LG Capital”), pursuant to which LG Capital purchased a convertible promissory note (the “February 19, 2020 LG Capital Note”) from the Company in the aggregate principal amount of $ 75,000 3,750 2,500 71,250 February 19, 2021 8 During the first 60 to 180 days following the date of the note, the Company had the right to prepay the principal and accrued but unpaid interest due under the February 19, 2020 LG Capital Note, together with any other amounts that the Company may owe the holder under the terms of the note, at a premium ranging from 112 135 The conversion price for the February 19, 2020 LG Capital Note during the first 6 months the February 19, 2020 LG Capital Note was fixed at $500 and thereafter was equal to a 35% discount of the lowest closing bid price (“Lowest Trading Price”) of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion, including the day upon which a Notice of Conversion was received. Notwithstanding the foregoing, LG Capital was restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by LG Capital and its affiliates, exceeds 9.99 40,385 The February 19, 2020 LG Capital Note contained certain events of default, upon which principal and accrued interest would become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal would accrue at a default interest rate of 24 The total principal amount outstanding under the above LG Capital financing agreement was $ 75,000 2,164 0 75,000 5,421 40,385 There were 9,427 10,000 416 5,385 15,801 Geneva Roth Remark Securities Purchase Agreements December 2, 2020 Securities Purchase Agreement Effective December 2, 2020, the Company entered into a securities purchase agreement with Geneva Roth Remark Holdings, Inc.(“Geneva Roth”), pursuant to which Geneva Roth purchased a convertible promissory note (the “December 2, 2020 Geneva Roth”) from the Company in the aggregate principal amount of $ 78,000 3,000 December 2, 2021 8 January 5, 2021 Securities Purchase Agreement Effective January 5, 2021, the Company entered into a securities purchase agreement with Geneva Roth Remark Holdings, Inc., pursuant to which Geneva Roth purchased a convertible promissory note (the “January 5, 2021 Geneva Roth”) from the Company in the aggregate principal amount of $ 68,500 3,500 January 5, 2022 8 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 March 16, 2021 Securities Purchase Agreement Effective March 16, 2021, the Company entered into a securities purchase agreement with Geneva Roth Remark Holdings, Inc., pursuant to which Geneva Roth purchased a convertible promissory note (the “March 16, 2021 Geneva Roth”) from the Company in the aggregate principal amount of $ 63,500 3,500 The maturity date of the March 16, 2021 Geneva Roth Note was March 16, 2022 8 August 19, 2021 Securities Purchase Agreement Effective August 19, 2021, the Company entered into a securities purchase agreement with Geneva Roth Remark Holdings, Inc., pursuant to which Geneva Roth purchased a convertible promissory note (the “August 19, 2021 Geneva Roth”) from the Company in the aggregate principal amount of $ 103,750 3,750 August 19, 2022 8 September 22, 2021 Securities Purchase Agreement Additionally, effective September 22, 2021, the Company entered into a securities purchase agreement with Geneva Roth Remark Holdings, Inc., pursuant to which Geneva Roth purchased a convertible promissory note (the “September 22, 2021 Geneva Roth”) from the Company in the aggregate principal amount of $ 63,750 September 22, 2022 8 During the first 60 to 180 days following the date of these notes, the Company had the right to prepay the principal and accrued but unpaid interest due under the above notes issued to Geneva Roth, together with any other amounts that the Company may owe the holder under the terms of the note, at a premium ranging from 110 129 The conversion price for the above Geneva Roth notes was equal to a 35 9.99 203,269 The above Geneva Roth notes contained certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 22 The total principal amounts outstanding under the above Geneva Roth financing agreements were $ 132,000 3,477 78,000 3,120 42,000 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 The total principal amounts outstanding under the above Geneva Roth financing agreements were $ 0 299,500 11,980 161,269 1800 Diagonal Lending (formerly known as Sixth Street Lending) Securities Purchase Agreements October 21, 2021 Securities Purchase Agreement Effective October 21, 2021, the Company entered into a securities purchase agreement with Sixth Street Lending LLC (“Sixth Street”), pursuant to which Sixth Street purchased a convertible promissory note (the “October 21, 2021 Sixth Street”) from the Company in the aggregate principal amount of $ 63,750 3,750 October 21, 2022 8 November 26, 2021 Securities Purchase Agreement Effective November 26, 2021, the Company entered into a securities purchase agreement with Sixth Street Lending LLC pursuant to which Sixth Street purchased a convertible promissory note (the “November 26, 2021 Sixth Street”) from the Company in the aggregate principal amount of $ 53,750 3,750 November 26, 2022 8 January 4, 2022 Securities Purchase Agreement Additionally, effective January 4, 2022, the Company entered into a securities purchase agreement with Sixth Street Lending LLC pursuant to which Sixth Street purchased a convertible promissory note (the “January 4, 2022 Sixth Street”) from the Company in the aggregate principal amount of $ 63,750 3,750 January 4, 2023 8 March 7, 2022 Securities Purchase Agreement Additionally, effective March 7, 2022, the Company entered into a securities purchase agreement with Sixth Street Lending LLC pursuant to which Sixth Street purchased a convertible promissory note (the “March 7, 2022 Sixth Street”) from the Company in the aggregate principal amount of $ 68,750 3,750 March 7, 2023 8 April 12, 2022 Securities Purchase Agreement Effective April 12, 2022, the Company entered into a securities purchase agreement with Sixth Street Lending LLC, pursuant to which Sixth Street purchased a convertible promissory note (the “April 12, 2022 Sixth Street”) from the Company in the aggregate principal amount of $ 68,750 3,750 April 12, 2023 8 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 May 12, 2022 Securities Purchase Agreement Effective May 12, 2022, the Company entered into a securities purchase agreement with 1800 Diagonal Lending LLC (“1800 Diagonal”), pursuant to which 1800 Diagonal purchased a convertible promissory note (the “May 12, 2022 1800 Diagonal Note”) from the Company in the aggregate principal amount of $ 63,750 3,750 May 12, 2023 8 During the first 60 to 180 days following the date of the above listed notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the above notes issued, together with any other amounts that the Company may owe the holder under the terms of the note, at a premium ranging from 110 129 The conversion price for the above 1800 Diagonal notes shall be equal to a 35 9.99 205,962 The above 1800 Diagonal notes contain certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 22 Other than as described above, the above 1800 Diagonal notes contain certain events of default, including failure to timely issue shares upon receipt of a notice of conversion, as well as certain customary events of default, including, among others, breach of covenants, representations or warranties, insolvency, bankruptcy, liquidation and failure by the Company to pay the principal and interest due under the Note. Additional events of default shall include, among others: (i) failure to reserve at least five times the number of shares issuable upon full conversion of the Note; (ii) bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings, voluntary or involuntary, for relief under any bankruptcy law or any law for the relief of debtors shall be instituted by or against the Company or any subsidiary of the Company; provided, that in the event such event is triggered without the Company’s consent, the Company shall have sixty (60) days after such event is triggered to discharge such event, (iii) the Company’s failure to maintain the listing of the common stock on at least one of the OTC markets (which specifically includes the quotation platforms maintained by the OTC Markets Group) or an equivalent replacement exchange, the Nasdaq National Market, the Nasdaq Small Cap Market, the New York Stock Exchange, or the American Stock Exchange, (iv) The restatement of any financial statements filed by the Company with the SEC at any time after 180 days after the issuance date for any date or period until this note is no longer outstanding, if the result of such restatement would, by comparison to the un-restated financial statement, have reasonably constituted a material adverse effect on the rights of 1800 Diagonal with respect to this note or the Purchase Agreement, and (v) the Company’s failure to comply with its reporting requirements of the Securities and Exchange Act of 1934 (the “Exchange Act”), and/or the Company ceases to be subject to the reporting requirements of the Exchange Act. In the event that the Company fails to deliver the shares of common stock issuable upon conversion of principal or interest under the above 1800 Diagonal notes within three business days of a notice of conversion by 1800 Diagonal, the Company shall incur a penalty of $ 1,000 Upon the occurrence and during the continuation of certain events of default, the above 1800 Diagonal notes will become immediately due and payable and the Company will pay 1800 Diagonal in full satisfaction of its obligations in the amount equal to 150 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 The total principal amount outstanding under the above Sixth Street financing agreements were $ 265,000 6,081 117,500 4,700 63,269 ONE44 Capital Securities Purchase Agreements December 7, 2021 Securities Purchase Agreement Effective December 7, 2021, the Company entered into a securities purchase agreement with ONE44 Capital LLC (“ONE44”), pursuant to which ONE44 purchased a convertible promissory note (the “December 7, 2021 ONE44”) from the Company in the aggregate principal amount of $ 170,000 25,500 December 7, 2022 10 March 29, 2022 Securities Purchase Agreement Effective March 29, 2022, the Company entered into a securities purchase agreement with ONE44 Capital LLC, pursuant to which ONE44 purchased a convertible promissory note (the “March 29, 2022 ONE44”) from the Company in the aggregate principal amount of $ 120,000 18,000 March 29, 2023 10 During the first 60 to 180 days following the date of these notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the above notes issued to ONE44, together with any other amounts that the Company may owe the holder under the terms of the note, at a premium ranging from 120 135 The conversion price for the above ONE44 notes shall be equal to a 65 4.99 156,154 The above ONE44 notes contain certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 24 250 th 500 th 20 The total principal amount outstanding under the above ONE44 financing agreements were $ 235,700 9,519 54,300 2,873 29,238 Convertible notes in default There are two convertible notes that are currently past due and are in default, consisting of $ 144,280 33,930 15% 18% Amortization of debt discounts The Company recorded $ 73,500 211,000 452,308 498,160 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 Amortization of all debt discounts for the years ended June 30, 2022 and 2021 was $ 47,971 136,527 The Company reclassified $ 335,677 and $ 590,504 in put premiums to additional paid in capital following conversions during the year ended June 30, 2022 and 2021, respectively.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 7 – INCOME TAXES The Company follows ASC 740-10-10, under which an entity recognizes deferred tax assets and liabilities for future tax consequences or for events that were previously recognized in the Company’s financial statements or tax returns. The measurement of deferred tax assets and liabilities is based on enacted tax law provisions. The effects of future changes in tax laws or rates are not anticipated. Through June 30, 2010, the Company operated exclusively in Australia. The Company was wholly subject to Australian income tax laws and regulations, which are administered by the Australian Taxation Office for the years ended June 30, 2010 and all prior years. On November 23, 2010, the Company was incorporated in the state of Delaware. In January 2011, the Company acquired all of the outstanding shares of Propanc PTY LTD on a one-for-one basis with Propanc PTY LTD becoming a wholly owned subsidiary of the Company. As a result of these transactions, the Company is subject to the income tax laws of both the United States and Australia for the years ended June 30, 2013 through June 30, 2022. The reconciliation of income tax expense computed at the U.S. federal statutory rate of 21 SCHEDULE OF INCOME TAX PROVISION Year Ended US June 30, 2022 June 30, 2021 Loss before Income taxes $ (2,658,087 ) $ (2,025,947 ) Taxes under statutory US tax rates $ (558,198 ) $ (425,449 ) Increase (decrease) in valuation allowance 339,334 1,146,001 Prior period adjustment - (1,063,710 ) Foreign tax rate differential (64,349 ) (51,169 ) Income tax rate change 272,008 392,767 Other 11,205 1,559 Income tax (expense) benefit $ - $ - The Company reflects a tax benefit on its consolidated statement of operations and comprehensive income (loss) in 2022 and 2021 of $ 54,977 113,415 On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. Significant components of the Company’s deferred tax assets and liabilities consist of the following: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES Year Ended June 30, 2022 June 30, 2021 Deferred tax assets Warrant Derivative Liability $ 7,403 $ 7,403 Accrued Expenses 363,873 342,464 Prepaid Investor Services 427,318 444,411 Non-cash interest 709,936 687,529 Intangibles (Intellectual Property and Patent Cost) 293,260 259,743 Deferred Rent 4,198 4,262 Formation Expense 6,553 6,815 Net Operating Loss carryforward 8,759,357 8,546,920 Foreign Exchange Loss (OCI) (39,379 ) (39,379 ) Revalue of derivative liability 460,772 439,958 Stock Based Compensation 84,028 51,481 Total Deferred tax assets $ 11,077,318 $ 10,751,607 Deferred tax liabilities R&D $ (170,435 ) $ (197,604 ) Gain on extinguishment of debt (259,470 ) (277,614 ) Capital Raising Costs (352,981 ) (321,291 ) Total deferred tax liabilities $ (782,886 ) $ (796,509 ) Net deferred tax assets $ 10,294,432 $ 9,955,098 Valuation allowance (10,294,432 ) (9,955,098 ) Net deferred tax assets $ - $ - At June 30, 2022, the Company had U.S. net operating loss carry forwards of approximately $ 10,183,947 10.2 7.2 3.0 26 25 26,482,912 No The Company applied the “more-likely-than-not” recognition threshold to all tax positions taken or expected to be taken in a tax return, which resulted in no Management has determined that the realization of the net deferred tax asset is not assured and has created a valuation allowance for the entire amount of such benefits. The Company follows ASC 740-10, which provides guidance for the recognition and measurement of certain tax positions in an enterprise’s financial statements. Recognition involves a determination whether it is more likely than not that a tax position will be sustained upon examination with the presumption that the tax position will be examined by the appropriate taxing authority having full knowledge of all relevant information. The Company’s policy is to record interest and penalties associated with unrecognized tax benefits as additional income taxes in the consolidated statement of operations. As of June 30, 2022, the Company had no no The income tax returns filed for the tax years from inception will be subject to examination by the relevant taxing authorities.

STOCKHOLDERS_ DEFICIT

STOCKHOLDERS’ DEFICIT	12 Months Ended
	Jun. 30, 2022
Equity [Abstract]
STOCKHOLDERS’ DEFICIT	NOTE 8 – STOCKHOLDERS’ DEFICIT Increase in Authorized Shares of Common Stock and Reverse Stock Split On May 18, 2022, the board of directors of the Company approved and authorized, and the holders of a majority in interest of the Company’s voting capital stock approved by written consent, in accordance with Section 228 of the Delaware General Corporation Law, for the Company to file a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware, which increased the Company’s authorized capital stock. The Certificate increased the number of authorized shares of the Company’s common stock, par value $ 0.001 per share, from 1,000,000,000 to 3,000,000,000 . The number of authorized shares of preferred stock remains at 1,500,005 , such that the total number of shares of all classes and series the Company is authorized to issue is 3,001,500,005 shares. The Certificate was filed and became effective on July 6, 2022. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 On November 17, 2020, the Company effected a one-for-one thousand (1:1,000) Preferred Stock The total number of shares of preferred stock that the Company is authorized to issue is 1,500,005 0.01 Of the total preferred shares authorized, 500,000 500,000 Of the total preferred shares authorized, pursuant to the Certificate of Designation filed with the Secretary of State of the State of Delaware on June 16, 2015, up to five shares have been designated as Series B Preferred Stock (“Series B Preferred Stock”). Each holder of outstanding shares of Series B Preferred Stock is entitled to voting power equivalent to the number of votes equal to the total number of shares of common stock outstanding as of the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company and entitled to vote on all matters submitted or required to be submitted to a vote of the stockholders of the Company. One one No Common Stock Shares issued under the Equity Line On November 30, 2021, the Company entered into a Common Stock Purchase Agreement (the “Purchase Agreement”) with Dutchess Capital Growth Fund LP, a Delaware limited partnership, (“Dutchess”), providing for an equity financing facility (the “Equity Line”). The Purchase Agreement provides that upon the terms and subject to the conditions in the Purchase Agreement, Dutchess is committed to purchase up to Five Million Dollars ($ 5,000,000 36 Under the terms of the Purchase Agreement, Dutchess will not be obligated to purchase shares of Common Stock unless and until certain conditions are met, including but not limited to a Registration Statement on Form S-1 (the “Registration Statement”) becoming effective which registers Dutchess’ resale of any Common Stock purchased by Dutchess under the Equity Line. From time to time over the 36-month term of the Purchase Agreement, commencing on the trading day immediately following the date on which the Registration Statement becomes effective, the Company, in our sole discretion, may provide Dutchess with a draw down notice (each, a “Draw Down Notice”), to purchase a specified number of shares of Common Stock (each, a “Draw Down Amount Requested”), subject to the limitations discussed below. The actual amount of proceeds the Company will receive pursuant to each Draw Down Notice (each, a “Draw Down Amount”) is to be determined by multiplying the Draw Down Amount Requested by the applicable purchase price. The purchase price of each share of Common Stock equals 92 The maximum number of shares of Common Stock requested to be purchased pursuant to any single Draw Down Notice cannot exceed the lesser of (i) 300 250,000 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 The Company agreed to pay to Dutchess a commitment fee for entering into the Purchase Agreement of 1,000,000 1,000,000 0.02 20,000 20,000 20,000 Between April 5, 2022 and June 30, 2022, the Company issued an aggregate of 25,663,288 0.01 99,285 23,758 23,758 Shares issued for conversion of convertible debt During the year ended June 30, 2021, the Company issued an aggregate of 8,786,113 0.13 0.03 2.00 1,018,867 103,321 16,500 1,239,075 There were 24,427 19,600 416 11,785 31,801 During the year ended June 30, 2021, converted notes totaling principal amount of $ 95,000 3,000 178,368 80,368 130,975 The Company reclassified $ 590,504 During the year ended June 30, 2022, the Company issued an aggregate of 96,959,620 shares of its common stock and common stock issuable of 7,326,007 at average contractual conversion prices ranging from $ 0.01 to $ 0.04 , as a result of the conversion of principal of $ 599,148 , interest of $ 36,154 and conversion fees $ 2,250 underlying certain outstanding convertible notes converted during the year. The total recorded to equity was $ 657,125 including the $ 19,572 discussed below. The common stock issuable of 7,326,007 shares were issued on July 12, 2022. During the year ended June 30, 2022, converted notes - principal of $ 1,000 8,000 28,572 19,572 2,069 335,677 The Company has 730,181,169 Shares issued for services and accrued expenses On March 22, 2021, the Company issued an aggregate of 225,037 225,037 0.30 67,511 67,511 Between March 2021 and June 2021, the Company issued an aggregate of 580,609 580,609 0.10 58,061 58,061 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 On August 12, 2021, the Board approved the issuance of 2,800,000 84,000 2,800,000 0.03 87,920 3,920 84,000 On August 12, 2021, the Board approved the issuance of 166,667 166,667 0.05 7,883 7,883 In September 2021, the Company issued 2,819,712 shares of the Company’s common stock to a consultant for services rendered from July 2021 to September 2021 valued at approximately $ 0.04 per share or $ 104,611 , being the closing price of the stock on the date of grant to such consultant. The Company recorded stock-based compensation of $ 104,611 during the year ended June 30, 2022. On January 20, 2022, the Board approved the issuance of 666,667 666,667 0.03 20,000 20,000 On January 24, 2022, the Company issued 2,274,224 2,274,224 0.02 45,030 45,030 On February 17, 2022, the Board approved the issuance of 1,148,326 0.02 24,000 24,000 On April 13, 2022, the Company issued 3,833,683 3,833,683 0.0122 46,771 46,771 On June 30, 2022, the Board approved the issuance of 12,270,958 12,270,958 0.0037 45,403 45,403 12,270,958 Nathanielsz Cancellation Agreement On August 12, 2021, the Company entered into a Cancellation Agreement with James Nathanielsz (“Nathanielsz”), Chief Executive Officer and Director of the Company, whereby Nathanielsz agreed to cancel his cash compensation bonus award for fiscal year 2021, ended June 30, 2021, in exchange for common stock of the Company. The Company and Nathanielsz entered into an Amended and Restated Employment Agreement dated May 14, 2019 (the “Agreement”). Pursuant to the terms of the Agreement, Nathanielsz was eligible to earn an annual fiscal year cash performance bonus for each fiscal year of his employment period with the Company with a target performance bonus of 200 78 177,840 5,928,000 0.03 186,139 8,299 177,840 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 Kenyon Cancellation Agreement On August 12, 2021, the Company entered into a Cancellation Agreement with Dr. Julian Kenyon (“Kenyon”), Chief Scientific Officer and Director of the Company, whereby Kenyon agreed to cancel of $ 102,600 3,420,000 0.03 107,388 4,788 102,600 Zelinger Amended and Restated Director Agreement On August 12, 2021, the Company entered into an Amended and Restated Director Agreement (the “Director Agreement”) with Josef Zelinger (“Zelinger”). Pursuant to the terms of the Director Agreement, the Company shall pay Zelinger a base salary of $ 250.00 184 2,800,000 84,000 2,800,000 0.03 87,920 3,920 84,000 Shares issued for exercise of warrants During the year ended June 30, 2021, the Company received aggregate gross proceeds of $ 776,044 10,445 19,375 29,820 During the year ended June 30, 2022, the Company received aggregate gross proceeds of $ 625,000 15,625 40 15,625 Additionally, during the year ended June 30, 2021, the Company issued 4,199,979 56,799,716 284 200 0.001 200 70 700,340 391,749 Restricted Stock Units Pursuant to employment agreements dated in May 2019, the Company granted an aggregate of 78 39 117 4,250 497,240 248,620 59 248,620 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 Stock Options A summary of the Company’s stock option activity during the years ended June 30, 2022 and 2021 is presented below: SCHEDULE OF SHARE BASED COMPENSATION STOCK OPTIONS ACTIVITY Weighted Number of Average Options Price Per Share Outstanding at June 30, 2020 60 $ 76,370 Issued - - Exercised - - Expired (1 ) 3,750,000 Outstanding at June 30, 2021 59 $ 13,730 Issued - - Exercised - - Expired - - Outstanding at June 30, 2022 59 $ 4,533 Exercisable at June 30, 2022 59 $ 4,531 Outstanding and Exercisable: Weighted average remaining contractual term 6.88 Weighted average fair value of options granted during the period $ - Aggregate intrinsic value $ - On the Effective Date, the Company’s board of directors approved and adopted the Company’s 2019 Equity Incentive Plan (the “2019 Plan”), which reserves a total of 234 During the years ended June 30, 2022 and 2021, the Company recognized stock-based compensation of $ 72,513 82,872 0 No Stock Warrants The following table summarizes common stock warrant activity for the years ended June 30, 2022 and 2021: SCHEDULE OF WARRANT ACTIVITY Weighted Number of Average Warrants Price Per Share Outstanding at June 30, 2020 151,170 $ 150.00 Issued - - Exercised (29,841 ) 26.15 Forfeited - - Expired - - Outstanding at June 30, 2021 121,329 $ 179.63 Issued - - Exercised (15,909 ) 42.86 Forfeited - - Expired - - Outstanding at June 30, 2022 105,420 * $ 200.27 Exercisable at June 30, 2022 76,671 $ 275.37 Outstanding and Exercisable: Weighted average remaining contractual term 0.77 Aggregate intrinsic value $ - * The total warrants of 105,420 SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE Number of Warrants Exercisable Series A warrants 10,946 10,946 Series B warrants 28,750 28,750 Series C warrants 63,749 35,000 Warrants with no class designation 1,975 1,975 Total 105,420 76,671 In connection with the issuance of shares on April 3, 2020, the Company closed on a transaction related to a Securities Purchase Agreement (the “Securities Purchase Agreement”) entered into on March 30, 2020, whereby an investor purchased from the Company, 7,500 units, each consisting of (i) 1.5 shares of the Company’s common stock, or pre-funded warrants upon Investor’s election due to the 4.99% blocker provision and (ii) 1.5 warrants to purchase one share of Common Stock (“Series A Warrants”, and collectively with the Common Stock the “Units”). 63,750 63,750 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 Due to the Beneficial Ownership Limitation, the Company granted 10,445 0.10 Series A Warrants Pursuant to the Securities Purchase Agreement entered into March 20, 2020 as discussed above, the Investor purchased Series A Warrants to purchase up to 11,250 200 3 the Series A Warrants contain a provision for a cashless conversion at the Holder’s option should the trading price of the Common Stock fall below $200 per share calculated based on the difference between the exercise price of the Series A Warrant and 70% of the Market Price, as defined therein (the” Alternate Cashless Exercise”). The Alternate Cashless Exercise price is $0.001. Series B Warrants Pursuant to the Securities Purchase Agreement entered into March 20, 2020 as discussed above, the Investor purchased Series B Warrants to purchase up to 63,750 37,500 10 3,750 3,750 40 3 Series C Warrants Pursuant to the Securities Purchase Agreement entered into March 20, 2020 as discussed above, the Investor purchased Series C Warrants to purchase up to 63,750 3 200 Exercise of Warrants During the year ended June 30, 2021, the Company received aggregate gross proceeds of $ 776,044 10,445 19,375 29,820 4,199,979 During the year ended June 30, 2022, the Company received aggregate gross proceeds of $ 625,001 15,625 15,625 56,799,716

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 9 – COMMITMENTS AND CONTINGENCIES Legal Matters On September 26, 2019, a complaint was filed against the Company with Supreme Court of the State of New York, County of New York, by Foley Shechter Ablovatskiy LLP (“Foley Shechter”), our former counsel, seeking $ 151,031 51,032 51,032 142,660 92,556 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 Regal Consulting, LLC (“Regal”) initiated litigation against the Company in Clark County District Court, Nevada on November 18, 2019. Regal was demanding approximately $ 400,000 and 60 shares of the Company’s common stock as payment for services that Regal purports to have performed. Regal additionally claimed that $ 106,500 remained due on a Convertible Note executed by the Company in May of 2017 and asserted that it was owed in excess of $ 100,000 in penalties in connection with the Company’s refusal to honor certain Conversion Notices. The Company filed an Answer and Counterclaim, denying liability and alleging that Regal procured by fraud the Company’s execution of various consulting agreements and additionally failed to provide the consulting services contemplated by said agreements. On December 23, 2020, the parties mediated their dispute and negotiated a settlement agreement. On March 15, 2021, the Company entered into a Settlement and Mutual Release Agreement with Regal whereby both parties agreed to settle all claims and liabilities under the August 10, 2017 Convertible note (see Note 6) for a total of $ 100,000 . All other terms of the August 10, 2017 Convertible Note shall remain in full force and effect. Both parties agree that all future penalties under this convertible note are waived unless the Company fails to authorize the issuance of the requested shares upon conversion. The Company has the right to pay off the balance of any remaining amounts dues under this convertible note in cash at any time 61 days after March 15, 2021. Prior to the Settlement Agreement, the Company recorded total liabilities $ 56,762 consisting of remaining principal amount of $ 8,500 , accrued interest of $ 23,262 and accrued expenses of $ 25,000 . Accordingly, the Company recognized loss from settlement of debt of $ 43,238 during the year ended June 30, 2021. IRS Liability As part of its requirement for having a foreign operating subsidiary, the Company’s parent U.S. entity is required to file an informational Form 5471 to the Internal Revenue Service (the “IRS”), which is a form that explains the nature of the relationship between the foreign subsidiary and the parent company. From 2012 through the 2014, the Company did not file this form in a timely manner. As a result of the non-timely filings, the Company incurred a penalty from the IRS in the amount of $ 10,000 30,000 Operating Agreements In November 2009, the Company entered into a commercialization agreement with the University of Bath (UK) (the “University”) whereby the Company and the University co-owned the intellectual property relating to the Company’s pro-enzyme formulations. In June 2012, the Company and the University entered into an assignment and amendment whereby the Company assumed full ownership of the intellectual property while agreeing to pay royalties of 2 5 Operating Leases On May 5, 2016, the Company entered into a new five -year operating lease agreement with North Horizon Pty Ltd., a related party, of which Mr. Nathanielsz, our CEO, CFO and a director, and his wife are owners and directors, with monthly rent at $ 3,606 AUD or $ 2,469 USD (depending on exchange rate), inclusive of GST (see Note 10). The initial rental amount was $3,000 AUD and subject to 3% yearly escalation. Such lease expired in May 2021 and was renewed for another one-year term from May 2021 to May 2022. On May 4, 2022, the Company entered in a three-year lease agreement with North Horizon Pty Ltd. for a monthly rent of $ 3,000 AUD or $ 2,176 USD (depending on exchange rate) per month plus taxes. On May 4, 2022, the Company recorded right-of-use assets $ 66,201 and total lease liabilities of $ 66,201 based on an incremental borrowing rate of 8 %. ROU is summarized below: SCHEDULE OF RIGHT USE OF ASSET June 30, 2022 June 30, 2021 Office lease $ 66,201 $ 48,662 Less: accumulated amortization (3,678 ) (48,662 ) Right-of-use asset, net $ 62,523 $ - PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 Operating Lease liabilities are summarized below: SCHEDULE OF OPERATING LEASE LIABILITY June 30, 2022 June 30, 2021 Office lease $ 66,201 $ 48,662 Reduction of lease liability (3,277 ) (48,662 ) Less: office lease, current portion (20,605 ) - Long term portion of lease liability $ 42,319 $ - Remaining future minimum lease payments under non-cancelable operating lease at June 30, 2022 are as follows: SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS Fiscal Year 2023 $ 24,894 Fiscal Year 2024 24,894 Fiscal Year 2025 20,745 Imputed interest (7,609 ) Total operating lease liability $ 62,924 The weighted average remaining lease term for the operating lease is 2.77 Collaboration Agreement On September 13, 2018, the Company entered into a two-year collaboration agreement with the University of Jaén (the “University”) to provide certain research services to the Company. In consideration of such services, the Company agreed to pay the University approximately 52,000 59,508 40,000 45,775 31,754 36,117 28,493 24,043 30,000 35,145 5,000 5,000 5,858 10,000 11,715 10,000 11,715 25,837 30,268 2 Consulting Agreement On October 1, 2021, the Company entered into a consulting agreement (the “Consulting Agreement”) with a consultant who will assist in the development of the Company’s business and financing activities. The consultant will serve initially as an independent contractor, and upon certain mutually agreed upon conditions being met, will be appointed Vice Chairman, President and Interim CFO. The term of the Consulting Agreement was for three years commencing on October 1, 2021 and can be terminated by either party upon 30 day written notice. The monthly payment per the Consulting Agreement was $ 7,000 1,148,326 0.02 24,000 24,000

RELATED PARTY TRANSACTIONS AND

RELATED PARTY TRANSACTIONS AND BALANCES	12 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS AND BALANCES	NOTE 10 – RELATED PARTY TRANSACTIONS AND BALANCES Since its inception, the Company has conducted transactions with its directors and entities related to such directors. These transactions have included the following: As of June 30, 2022 and 2021, the Company owed its former director a total of $ 51,171 55,500 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 As of June 30, 2022 and 2021, the Company owed its former director a total of $ 30,746 33,347 Effective May 5, 2016, the Company entered into an agreement for the lease of its principal executive offices with North Horizon Pty Ltd., a related party, of which Mr. Nathanielsz, our CEO, CFO and a director, and his wife are owners and directors. The lease had a five 39,600 28,325 3,600 2,575 198,000 141,629 Such lease expired in May 2021 and was renewed for another one-year term from May 2021 to May 2022 three 3,000 2,176 122,129 84,452 86,129 64,597 28,366 28,112 Employment and Services Agreements with Management The Company and Mr. Nathanielsz entered into an employment agreement as of February 25, 2015 (the “Nathanielsz Employment Agreement”) setting forth the terms and conditions of Mr. Nathanielsz employment as the Company’s President and Chief Executive Officer. The Nathanielsz Employment Agreement was scheduled to expire on February 25, 2019 25,000 300,000 205,680 9.5 200 300,000 205,680 400,000 274,240 400,000 276,600 600,000 414,900 Mr. Nathanielsz’s wife, Sylvia Nathanielsz, is and has been a non-executive part-time employee of the Company since October 2015. Effective February 1, 2018, Mrs. Nathanielsz receives an annual salary of $ 120,000 80,904 Pursuant to a February 25, 2016 board resolution, James Nathanielsz shall be paid $ 4,481 3,205 46,135 34,476 7,689 5,577 Pursuant to the approval of the Company’s board of directors, on May 14, 2019, Mr. Nathanielsz was granted a $ 460,000 315,376 200,000 137,120 260,000 178,256 90,000 64,377 240,000 60 202,620 136,606 407,380 280,726 177,840 221,890 166,418 422,610 316,957 177,840 5,928,000 140,000 96,810 144,166 99,691 181,324 125,386 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 Amended and Restated Employment Agreement - On May 14, 2019 (the “Effective Date”), the Company entered into an Amended and Restated Employment Agreement (the “Employment Agreement”) with James Nathanielsz, the Company’s Chief Executive Officer, Chairman, acting Chief Financial Officer and a director, for a term of three years one 400,000 39 4,675 110 4,250 39 39 The Nathanielsz Options have a term of 10 7.80 7.80 4,000,000 7.80 7.80 39 Amended and Restated Services Agreement - On May 14, 2019, the Company also entered into an Amended and Restated Services Agreement (the “Services Agreement”) with Dr. Kenyon, the Company’s Chief Scientific Officer and a director, for a term of three one 54,000 20 4,250 100 20 20 The Kenyon Options have a term of 10 5 5 4,000,000 5 5 20 ursuant to the Cancellation Agreement, Mr. Kenyon agreed 102,600 3,420,000 54,000 37,341 135,000 101,250 Collaboration Agreement On October 1, 2020, the Company entered into a two-year collaboration agreement with the University of Jaén to provide certain research services to the Company (see Note 9). One of the Company’s Scientific Advisory Board is the lead joint researcher of University of Jaén. Additionally, on July 27, 2022, the Company entered into a two-year research agreement with the University of Jaén to provide certain research and experiment services to the Company (see Note 13). Further, the Company agreed to pay royalties of 1% of net revenues each to two members of the Scientific Advisory Board. Intercompany Loans All Intercompany loans were made by the parent to the subsidiary, Propanc PTY LTD, which have not been repaid as of June 30, 2022. Effective fiscal year 2021, the parent company determined that intercompany loans will not be repaid in the foreseeable future and thus, per ASC 830-20-35-3, gains and losses from measuring the intercompany balances are recorded within cumulative translation adjustment on the consolidated balance sheet as accumulated other comprehensive income. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021

CONCENTRATIONS AND RISKS

CONCENTRATIONS AND RISKS	12 Months Ended
	Jun. 30, 2022
Risks and Uncertainties [Abstract]
CONCENTRATIONS AND RISKS	NOTE 11 – CONCENTRATIONS AND RISKS Concentration of Credit Risk The Company maintains its cash in banks and financial institutions in Australia. Bank deposits in Australian banks are uninsured. The Company has not experienced any losses in such accounts through June 30, 2022. In fiscal year 2021, the Company primarily relied on funding from two convertible debt lenders and received net proceeds after deductions of $ 16,000 125,000 200,000 39 61 In fiscal year 2022, the Company primarily relied on funding from three convertible debt lenders and received net proceeds after deductions of $ 73,500 766,500 160,000 360,000 246,500 21 47 32 Receivable Concentration As of June 30, 2022 and 2021, the Company’s receivables were 100 Patent and Patent Concentration The Company has filed multiple patent applications relating to its lead product, PRP. The Company’s lead patent application has been granted and remains in force in the United States, Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Liechtenstein, Turkey, United Kingdom, Australia, China, Japan, Indonesia, Israel, New Zealand, Singapore, Malaysia, South Africa, Mexico, Republic of Korea, India and Brazil. In Canada, the patent application remains under examination. In 2016 and early 2017, we filed other patent applications. Three applications were filed under the Patent Cooperation Treaty (the “PCT”). The PCT assists applicants in seeking patent protection by filing one international patent application under the PCT, applicants can simultaneously seek protection for an invention in over 150 countries. Once filed, the application is placed under the control of the national or regional patent offices, as applicable, in what is called the national phase. One of the PCT applications filed in November 2016, entered national phase in July 2018 and another PCT application is currently entering national phase in August 2018. A third PCT application entered the national phase in October 2018. In July 2020, a world first patent was granted in Australia for the cancer treatment method patent family. Presently, there are 43 granted, allowed, or accepted patents and 22 patents filed, or under examination in key global jurisdictions relating to the use of proenzymes against solid tumors, covering the lead product candidate PRP. Further patent applications are expected to be filed to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer. Foreign Operations As of June 30, 2022 and 2021, the Company’s operations are based in Camberwell, Australia, however the majority of research and development is being conducted in the European Union. On July 22, 2016, the Company formed a wholly owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose of submitting an orphan drug application with the European Medicines Agency as a small and medium-sized enterprise. As of June 30, 2022 and 2021, there has been no activity within this entity.

DERIVATIVE FINANCIAL INSTRUMENT

DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	12 Months Ended
	Jun. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	NOTE 12 - DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Derivative Financial Instruments: The Company applies the provisions of ASC 815-40, Contracts in Entity’s Own Equity 79,000 80,000 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 The Company calculates the estimated fair values of the liabilities for derivative instruments using the Binomial Trees Method. The closing price of the Company’s common stock at June 30, 2022, the last trading day of the fiscal year ended June 30, 2022, was $ 0.0037 Convertible Debt SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES June 30, 2022 June 30, 2021 Volatility 228 % 222 % Expected remaining term 0.01 0.01 Risk-free interest rate 1.28 % 0.05 % Expected dividend yield None None Fair Value Measurements: The Company measures and reports at fair value the liability for derivative instruments. The fair value liabilities for price adjustable warrants and embedded conversion options have been recorded as determined utilizing the Binomial Trees model. The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2022: SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS Balance at Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 151,262 $ — $ — $ 151,262 Total $ 151,262 $ — $ — $ 151,262 The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2021: Balance at Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 54,220 $ — $ — $ 54,220 Total $ 54,220 $ — $ — $ 54,220 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 The following is a roll forward for the years ended June 30, 2022 and 2021 of the fair value liability of price adjustable derivative instruments: SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE Fair Value of Liability for Derivative Instruments Balance at June 30, 2020 $ 177,009 Gain on debt extinguishment (130,975 ) Change in fair value included in statements of operations 8,186 Balance at June 30, 2021 54,220 Gain on debt extinguishment (2,069 ) Change in fair value included in statements of operations 99,111 Balance at June 30, 2022 $ 151,262

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 13 – SUBSEQUENT EVENTS Exercise of warrants On August 2, 2022, the Company received gross proceeds of $ 50,000 1,250 1,250 Additionally, the Company issued an aggregate of 158,399,208 389,235 Shares issued for conversion of convertible debt From July 1, 2022 through September 14, 2022, the Company issued an aggregate of 264,492,661 0.001 327,200 22,330 133,646 Shares issued under the Equity Line On July 13, 2022, the Company issued 14,336,712 0.002 24,711 Issuance of convertible notes 1800 Diagonal Lending, LLC Securities Purchase Agreement On June 30, 2022, the Company entered into a securities purchase agreement with 1800 Diagonal Lending LLC (“1800 Diagonal”), which closed on July 11, 2022, pursuant to which 1800 Diagonal purchased a convertible promissory note (the “July 11, 2022 1800 Diagonal Note”) from the Company in the aggregate principal amount of $ 105,000 , such principal and the interest thereon convertible into shares of the Company’s common stock at the option of 1800 Diagonal any time after 180 days of the July 11, 2022 1800 Diagonal Note. The July 11, 2022 1800 Diagonal Note contains debt issue cost of $ 3,750 . The Company intends to use the net proceeds from the July 11, 2022 1800 Diagonal Note for general working capital purposes. The maturity date of the July 11, 2022 1800 Diagonal Note is June 30, 2023 . The 1800 Diagonal Note bears interest at a rate of 8 % per annum, which interest may be paid by the Company to 1800 Diagonal in shares of the Company’s common stock; but shall not be payable until the July 11, 2022 1800 Diagonal Note becomes payable, whether at the maturity date or upon acceleration or by prepayment. During the first 60 to 180 days following the date of these notes, the Company has the right to prepay the principal and accrued but unpaid interest due under the above note, together with any other amounts that the Company may owe the holder under the terms of the note, at a premium ranging from 110 129 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 The conversion price for the above note shall be equal to a 35 9.99 The above note contains certain events of default, upon which principal and accrued interest will become immediately due and payable. In addition, upon an event of default, interest on the outstanding principal shall accrue at a default interest rate of 22 GS Capital Partners, LLC Securities Purchase Agreement dated August 12, 2022 On August 12, 2022, the Company entered into a securities purchase agreement (the “GS Capital Purchase Agreement”) with GS Capital Partners, LLC (“GS Capital”), pursuant to which GS Capital purchased a convertible redeemable note (the “GS Capital Note”) from the Company in the aggregate principal amount of $ 93,000 5,000 3,000 The maturity date of the GS Capital Note is April 12, 2023 8 The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. GS Capital is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Capital Note then outstanding into shares of the Company’s common stock at a price for each share of Common Stock (“Conversion Price”) of $0.0028 per share (the “Fixed Price”). However, in the event the Company’s common stock trades below $0.002 per share for more than five (5) consecutive trading days, then the Fixed Price shall be equal to $0.0013 per share. 65 4.99 During the first 60 to 180 days following the date of this note, the Company has the right to prepay the principal and accrued but unpaid interest due under the above note issued to GS Capital, together with any other amounts that the Company may owe the holder under the terms of the note, at a premium ranging from 110 130 Upon the occurrence and during the continuation of certain events of default, interest shall accrue at a default interest rate of 24 % per annum or, if such rate is usurious or not permitted by current law, then at the highest rate of interest permitted by law. In the event that the Company fails to deliver to GS Capital shares of common stock issuable upon conversion of principal or interest under the GS Capital Note, the penalty shall be $ 250 per day the shares are not issued beginning on the 4 th 500 per day beginning on the 10 th In an event of breach of section 8m as defined in the GS Capital note agreement, such GS Capital note shall incur penalty and will increase the outstanding principal amounts by 20 GS Capital Partners, LLC Securities Purchase Agreement dated September 21, 2022 On September 21, 2022, the Company entered into a securities purchase agreement with GS Capital Partners, LLC, pursuant to which GS Capital purchased a convertible redeemable note from the Company in the aggregate principal amount of $ 71,500 , such principal and the interest thereon convertible into shares of the Company’s common stock at the option of GS Capital. The transaction contemplated by the GS Capital Purchase Agreement closed on September 26, 2022. The GS Capital Note contains a $ 4,000 original issue discount. Pursuant to the terms of the GS Purchase Agreement, the Company paid GS Capital’s legal fees of $ 2,500 . The Company intends to use the net proceeds ($67,500) from the GS Capital Note for general working capital purposes. The maturity date of the GS Capital Note is March 21, 2023 8 The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. GS Capital is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Capital Note then outstanding into shares of the Company’s common stock (the “Common Stock”) at a price for each share of Common Stock (“Conversion Price”) of $0.002 per share (the “Fixed Price”). However, in the event the Company’s Common Stock trades below $0.0014 per share for more than five (5) consecutive trading days, then the Fixed Price shall be equal to $0.0009 per share. 65 4.99 During the first 60 to 180 days following the date of this note, the Company has the right to prepay the principal and accrued but unpaid interest due under the above note issued to GS Capital, together with any other amounts that the Company may owe the holder under the terms of the note, at a premium ranging from 110 125 Upon the occurrence and during the continuation of certain events of default, interest shall accrue at a default interest rate of 24 250 th 500 th 20 ONE44 Capital LLC Securities Purchase Agreement On August 15, 2022, the Company entered into a securities purchase agreement (the “ONE44 Purchase Agreement”) with ONE44 Capital LLC, (“ONE44 Capital”), pursuant to which ONE44 Capital purchased a convertible redeemable note (the “ONE44 Note”) from the Company in the aggregate principal amount of $ 110,000 10,000 5,500 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 The maturity date of the One44 Note is August 15, 2023 . The ONE44 Note shall bear interest at a rate of 10% per annum, which interest may be paid by the Company to ONE44 Capital in shares of common stock, but shall not be payable until the ONE44 Note becomes payable, whether at the Maturity Date or upon acceleration or by prepayment, as described below. The ONE44 Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by ONE44 surrendering the same. ONE44 Capital has the option to convert all or any amount of the principal face amount of the ONE44 Note at any time after the 6 th 65 % multiplied by the lowest closing bid price of the Company’s common stock as reported on the OTC Markets on which the Company’s shares are then traded or any exchange upon which the Common Stock may be traded in the future, for the ten prior trading days including the day upon which a Notice of Conversion is received by the Company. Notwithstanding the foregoing, ONE44 shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by ONE44 and its affiliates, exceeds 4.99 % of the outstanding shares of the Company’s common stock. The Company treats this convertible note as stock settled debt under ASC 480. During the first 60 to 180 days following the date of this note, the Company has the right to prepay the principal and accrued but unpaid interest due under the above note issued to GS Capital, together with any other amounts that the Company may owe the holder under the terms of the note, at a premium ranging from 120 135 Upon the occurrence and during the continuation of certain events of default, the ONE44 Note will accrue an interest rate of 24 %. In the event that the Company fails to deliver to ONE44 Capital shares of common stock issuable upon conversion of principal or interest under the ONE44 Capital Note, the penalty shall be $ 250 per day the shares are not issued beginning on the 4 th 500 per day beginning on the 10 th y. In an event of breach of section 8m as defined in the ONE44 note agreement, such ONE44 note shall incur penalty and will increase the outstanding principal amounts by 20 Research Agreement On July 27, 2022, the Company entered into a two-year research agreement with the University of Jaén (the “University”) to provide certain research and experiment services to the Company. In exchange for full ownership of the intellectual property the Company agreed to pay royalties of 2 53,200 Euros ($ 53,806 USD) payable as follows: - 18,200 18,407 - 8,000 8,091 - 7,000 7,080 - 10,000 10,114 - 10,000 10,114 The commencement date for the experiments is on September 1, 2022, and the estimated length of time for completion is 24 months. Consulting Agreement On July 1, 2022, the Company and a consultant agreed to extend the term of a consulting agreement from July 1, 2022 to June 30, 2023 to provide media related services for a monthly fee of $ 50,000 9.9 9.9%

NATURE OF OPERATIONS AND SUMM_2

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES (Policies)	12 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Nature of Operations	Nature of Operations Propanc Biopharma, Inc. (the “Company,” “we,” “us” or “our”) was originally incorporated in Melbourne, Victoria Australia on October 15, 2007 as Propanc PTY LTD, and continues to be based in Camberwell, Victoria Australia. Since its inception, substantially all of the operations of the Company have been focused on the development of new cancer treatments targeting high-risk patients, particularly cancer survivors, who need a follow-up, non-toxic, long-term therapy designed to prevent the cancer from returning and spreading. The Company anticipates establishing global markets for its technologies. Our lead product candidate, which we refer to as PRP, is an enhanced pro-enzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. It is currently in the preclinical phase of development. On November 23, 2010, the Company was incorporated in the state of Delaware as Propanc Health Group Corporation. In January 2011, to reorganize the Company, we acquired all of the outstanding shares of Propanc PTY LTD on a one-for-one basis making it a wholly-owned subsidiary of the Company. On July 22, 2016, the Company formed a wholly owned subsidiary, Propanc (UK) Limited under the laws of England and Wales for the purpose of submitting an orphan drug application to the European Medicines Agency as a small and medium-sized enterprise. As of June 30, 2022, there has been no activity within this entity. Effective April 20, 2017, the Company changed its name to “Propanc Biopharma, Inc.” to better reflect the Company’s stage of operations and development. In July 2020, a world first patent was granted in Australia for the cancer treatment method patent family. Presently, there are 43 granted, allowed, or accepted patents and 22 patents filed, or under examination in key global jurisdictions relating to the use of proenzymes against solid tumors, covering the lead product candidate PRP. The Company hopes to capture and protect additional patentable subject matter based on the Company’s field of technology relating to pharmaceutical compositions of proenzymes for treating cancer by filing additional patent applications as it advances its lead product candidate, PRP, through various stages of development. On November 17, 2020, the Company effected a one-for-one thousand On May 18, 2022, the board of directors of the Company approved and authorized, and the holders of a majority in interest of the Company’s voting capital stock approved by written consent, in accordance with Section 228 of the Delaware General Corporation Law, for the Company to file a Certificate of Amendment to its Certificate of Incorporation (the “Certificate”) with the Secretary of State of the State of Delaware, which increased the Company’s authorized capital stock. The Certificate increased the number of authorized shares of the Company’s common stock, par value $ 0.001 1,000,000,000 3,000,000,000 1,500,005 3,001,500,005
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Propanc Biopharma, Inc., the parent entity, and its wholly-owned subsidiary, Propanc PTY LTD. All inter-company balances and transactions have been eliminated in consolidation. Propanc (UK) Limited was an inactive wholly-owned subsidiary through June 30, 2022.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with the accounting principles generally accepted in the United States of America (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Significant estimates in the accompanying consolidated financial statements include the estimates of useful lives for depreciation, valuation of the operating lease liability and related right-of-use asset, valuation of derivatives, valuation of beneficial conversion features on convertible debt, allowance for uncollectable receivables, valuation of equity based instruments issued for other than cash, the valuation allowance on deferred tax assets and foreign currency translation due to certain average exchange rates applied in lieu of spot rates on transaction dates. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021
Foreign Currency Translation and Other Comprehensive Income (Loss)	Foreign Currency Translation and Other Comprehensive Income (Loss) The Company’s wholly owned subsidiary’s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into the Company’s reporting currency which is the United States dollar ($) and/or (USD). Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “Accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency transactions are included in the statements of operations and comprehensive income (loss) as a component of other comprehensive income (loss). There have been no significant fluctuations in the exchange rate for the conversion of Australian dollars to USD after the balance sheet date. Other Comprehensive Income (Loss) for all periods presented includes only foreign currency translation gains (losses). Assets and liabilities denominated in foreign currencies are translated into the functional currency at the exchange rates prevailing at the consolidated balance sheet date with any transaction gains and losses that arise from exchange rate fluctuations on transactions denominated in a currency other than the functional currency included in the consolidated results of operations as incurred. Effective fiscal year 2021, the parent company determined that the intercompany loans will not be repaid in the foreseeable future and thus, per ASC 830-20-35-3, gains and losses from measuring the intercompany balances are recorded within cumulative translation adjustment, a component of accumulated other comprehensive income (loss). Prior to July 1, 2020, the Company recorded the foreign currency transaction gains and losses from measuring the intercompany balances as a component of other income (expenses) titled foreign currency transaction gain (loss). For the year ended June 30, 2022 and 2021, the Company recognized an exchange gain (loss) of approximately $ 1,289,000 $1,005,000 As of June 30, 2022 and 2021, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: SCHEDULE OF TRANSLATION EXCHANGE RATES June 30, 2022 June 30, 2021 Exchange rate on balance sheet dates USD : AUD exchange rate 0.6915 0.7500 Average exchange rate for the period USD : AUD exchange rate 0.7253 0.7473 Change in Accumulated Other Comprehensive Income (Loss) by component during the years ended June 30, 2022 and 2021 were as follows: SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS Foreign Beginning balance, June 30, 2020 $ 1,267,671 Foreign currency translation gain 182,467 Balance, June 30, 2021 1,085,204 Foreign currency translation gain 149,345 Ending balance, June 30, 2022 $ 1,234,549
Fair Value of Financial Instruments and Fair Value Measurements	Fair Value of Financial Instruments and Fair Value Measurements The Company measures its financial assets and liabilities in accordance with US GAAP. For certain financial instruments, including cash and cash equivalents, receivables, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for notes payable, net of discount, and loans payable also approximate fair value because current interest rates available for debt with similar terms and maturities are substantially the same. The Company follows accounting guidance for financial assets and liabilities. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use. Also see Note 12 - Derivative Financial Instruments and Fair Value Measurements.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less with financial institutions, and bank overdrafts. Bank overdrafts, as applicable, are reflected as a current liability on the balance sheets. There were no
Property and Equipment	Property and Equipment Property and equipment are stated at cost, net of accumulated depreciation. Expenditures for maintenance and repairs are expensed as incurred; additions, renewals, and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method. The depreciable amount is the cost less its residual value. The estimated useful lives are as follows: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVE Machinery and equipment - 5 Furniture - 7
Patents	Patents Patents are stated at cost and amortized on a straight-line basis over the estimated future periods if and once the patent has been granted by a regulatory agency. However, the Company will expense any patent costs as long as we are in the startup stage. Accordingly, as the Company’s products are not currently approved for market, all patent costs incurred from 2013 through June 30, 2022 were expensed immediately. This practice of expensing patent costs immediately ends when a product receives market authorization from a government regulatory agency.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets In accordance with ASC 360-10, “Long-lived assets,” which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Fair value is generally determined using the asset’s expected future discounted cash flows or market value, if readily determinable.
Employee Benefit/Liability	Employee Benefit/Liability Liabilities arising in respect of wages and salaries, accumulated annual leave, accumulated long service leave and any other employee benefits expected to be settled within twelve months of the reporting date are measured based on the employee’s remuneration rates applicable at the reporting date. All other employee benefit liabilities are measured at the present value of the estimated future cash outflow to be made in respect of services provided by employees up to the reporting date. All employee liabilities are owed within the next twelve months. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021
Australian Goods and Services Tax (“GST”)	Australian Goods and Services Tax (“GST”) Revenues, expenses and balance sheet items are recognized net of the amount of GST, except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office. Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows. As of June 30, 2022 and 2021, the Company was owed $ 2,342 4,341
Derivative Instruments	Derivative Instruments ASC Topic 815, Derivatives and Hedging
Convertible Notes With Variable Conversion Options	Convertible Notes With Variable Conversion Options The Company has entered into convertible notes, some of which contain variable conversion options, whereby the outstanding principal and accrued interest may be converted, by the holder, into common shares at a fixed discount to the price of the common stock at or around the time of conversion. The Company treats these convertible notes as stock settled debt under ASC 480, “ Distinguishing Liabilities from Equity
Income Taxes	Income Taxes The Company is governed by Australia and United States income tax laws, which are administered by the Australian Taxation Office and the United States Internal Revenue Service, respectively. The Company follows ASC 740 “ Accounting for Income Taxes The Company follows ASC 740, Sections 25 through 60, “ Accounting for Uncertainty in Income Taxes
Research and Development Costs and Tax Credits	Research and Development Costs and Tax Credits In accordance with ASC 730-10, “Research and Development-Overall,” 256,052 230,956 The Company may apply for research and development tax concessions with the Australian Taxation Office on an annual basis. Although the amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income, then the Company can receive the credit which reduces its income tax liability. If the Company has net losses, then the Company may still receive a cash payment for the credit, however, the Company’s net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as tax benefit, in operations, upon receipt. PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021 During each of the fiscal years ended June 30, 2022 and 2021, the Company applied for, and received from the Australian Taxation Office, a research and development tax credit in the amount of $ 54,977 113,415
Stock Based Compensation	Stock Based Compensation The Company records stock-based compensation in accordance with ASC 718, “ Stock Compensation The Company adopted ASU 2018-07 and accounts for non-employee share-based awards in accordance with the measurement and recognition criteria of ASC 718 and recognizes the fair value of such awards over the service period. The Company used the modified prospective method of adoption.
Revenue Recognition	Revenue Recognition The Company applies ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). ASC 606 establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures. Subject to these criteria, the Company intends to recognize revenue relating to royalties on product sales in the period in which the sale occurs and the royalty term has begun.
Legal Expenses	Legal Expenses All legal costs for litigation are charged to expense as incurred.
Leases	Leases The Company follows ASC Topic 842, Leases (Topic 842) and applies the package of practical expedients, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 month or less. Operating lease right of use assets (“ROU”) represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses.
Basic and Diluted Net Loss Per Common Share	Basic and Diluted Net Loss Per Common Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options, warrants and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. Each holder of the notes has agreed to a 4.99 9.99 SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE June 30, 2022 June 30, 2021 Stock Options 59 59 Stock Warrants 105,420 121,329 Unvested restricted stock 59 59 Convertible Debt 127,062,326 12,416,972 Total 127,167,864 12,538,419 PROPANC BIOPHARMA, INC. AND SUBSIDIARY NOTES TO CONSOLIDATED FINANCIAL STATEMENTS June 30, 2022 and 2021
Recent Accounting Pronouncements	Recent Accounting Pronouncements We have reviewed the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. We have carefully considered the new pronouncements that alter previous generally accepted accounting principles and do not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term with the exception of those disclosed below. The applicability of any standard is subject to the formal review of the Company’s financial management. In August 2020, the FASB issued ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40)”. This ASU reduces the number of accounting models for convertible debt instruments and convertible preferred stock as well as amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. In addition, this ASU improves and amends the related EPS guidance. This standard is effective for us on July 1, 2024, including interim periods within those fiscal years. Adoption is either a modified retrospective method or a fully retrospective method of transition. The Company is currently assessing the impact of the new guidance will have on our consolidated financial statements.

NATURE OF OPERATIONS AND SUMM_3

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES (Tables)	12 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
SCHEDULE OF TRANSLATION EXCHANGE RATES	As of June 30, 2022 and 2021, the exchange rates used to translate amounts in Australian dollars into USD for the purposes of preparing the consolidated financial statements were as follows: SCHEDULE OF TRANSLATION EXCHANGE RATES June 30, 2022 June 30, 2021 Exchange rate on balance sheet dates USD : AUD exchange rate 0.6915 0.7500 Average exchange rate for the period USD : AUD exchange rate 0.7253 0.7473
SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS	Change in Accumulated Other Comprehensive Income (Loss) by component during the years ended June 30, 2022 and 2021 were as follows: SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS Foreign Beginning balance, June 30, 2020 $ 1,267,671 Foreign currency translation gain 182,467 Balance, June 30, 2021 1,085,204 Foreign currency translation gain 149,345 Ending balance, June 30, 2022 $ 1,234,549
SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVE	The estimated useful lives are as follows: SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVE Machinery and equipment - 5 Furniture - 7
SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE	SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE June 30, 2022 June 30, 2021 Stock Options 59 59 Stock Warrants 105,420 121,329 Unvested restricted stock 59 59 Convertible Debt 127,062,326 12,416,972 Total 127,167,864 12,538,419

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Jun. 30, 2022
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY PLANT AND EQUIPMENT	Property and equipment consist of the following as of June 30: SCHEDULE OF PROPERTY PLANT AND EQUIPMENT 2022 2021 Office equipment at cost $ 28,623 $ 28,623 Less: Accumulated depreciation (26,600 ) (24,368 ) Total property, plant, and equipment $ 2,023 $ 4,255

CONVERTIBLE NOTES (Tables)

CONVERTIBLE NOTES (Tables)	12 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
SCHEDULE OF CONVERTIBLE NOTES	The Company’s convertible notes outstanding at June 30, 2022 and 2021 were as follows: SCHEDULE OF CONVERTIBLE NOTES June 30, 2022 June 30, 2021 Convertible notes and debenture $ 644,980 $ 400,128 Unamortized discounts (31,669 ) (6,139 ) Accrued interest 57,822 34,098 Premium, net 313,127 196,496 Convertible notes, net $ 984,260 $ 624,583

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
SCHEDULE OF INCOME TAX PROVISION	The reconciliation of income tax expense computed at the U.S. federal statutory rate of 21 SCHEDULE OF INCOME TAX PROVISION Year Ended US June 30, 2022 June 30, 2021 Loss before Income taxes $ (2,658,087 ) $ (2,025,947 ) Taxes under statutory US tax rates $ (558,198 ) $ (425,449 ) Increase (decrease) in valuation allowance 339,334 1,146,001 Prior period adjustment - (1,063,710 ) Foreign tax rate differential (64,349 ) (51,169 ) Income tax rate change 272,008 392,767 Other 11,205 1,559 Income tax (expense) benefit $ - $ -
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES	SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES Year Ended June 30, 2022 June 30, 2021 Deferred tax assets Warrant Derivative Liability $ 7,403 $ 7,403 Accrued Expenses 363,873 342,464 Prepaid Investor Services 427,318 444,411 Non-cash interest 709,936 687,529 Intangibles (Intellectual Property and Patent Cost) 293,260 259,743 Deferred Rent 4,198 4,262 Formation Expense 6,553 6,815 Net Operating Loss carryforward 8,759,357 8,546,920 Foreign Exchange Loss (OCI) (39,379 ) (39,379 ) Revalue of derivative liability 460,772 439,958 Stock Based Compensation 84,028 51,481 Total Deferred tax assets $ 11,077,318 $ 10,751,607 Deferred tax liabilities R&D $ (170,435 ) $ (197,604 ) Gain on extinguishment of debt (259,470 ) (277,614 ) Capital Raising Costs (352,981 ) (321,291 ) Total deferred tax liabilities $ (782,886 ) $ (796,509 ) Net deferred tax assets $ 10,294,432 $ 9,955,098 Valuation allowance (10,294,432 ) (9,955,098 ) Net deferred tax assets $ - $ -

STOCKHOLDERS_ DEFICIT (Tables)

STOCKHOLDERS’ DEFICIT (Tables)	12 Months Ended
	Jun. 30, 2022
Equity [Abstract]
SCHEDULE OF SHARE BASED COMPENSATION STOCK OPTIONS ACTIVITY	A summary of the Company’s stock option activity during the years ended June 30, 2022 and 2021 is presented below: SCHEDULE OF SHARE BASED COMPENSATION STOCK OPTIONS ACTIVITY Weighted Number of Average Options Price Per Share Outstanding at June 30, 2020 60 $ 76,370 Issued - - Exercised - - Expired (1 ) 3,750,000 Outstanding at June 30, 2021 59 $ 13,730 Issued - - Exercised - - Expired - - Outstanding at June 30, 2022 59 $ 4,533 Exercisable at June 30, 2022 59 $ 4,531 Outstanding and Exercisable: Weighted average remaining contractual term 6.88 Weighted average fair value of options granted during the period $ - Aggregate intrinsic value $ -
SCHEDULE OF WARRANT ACTIVITY	The following table summarizes common stock warrant activity for the years ended June 30, 2022 and 2021: SCHEDULE OF WARRANT ACTIVITY Weighted Number of Average Warrants Price Per Share Outstanding at June 30, 2020 151,170 $ 150.00 Issued - - Exercised (29,841 ) 26.15 Forfeited - - Expired - - Outstanding at June 30, 2021 121,329 $ 179.63 Issued - - Exercised (15,909 ) 42.86 Forfeited - - Expired - - Outstanding at June 30, 2022 105,420 * $ 200.27 Exercisable at June 30, 2022 76,671 $ 275.37 Outstanding and Exercisable: Weighted average remaining contractual term 0.77 Aggregate intrinsic value $ - * The total warrants of 105,420
SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE	SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE Number of Warrants Exercisable Series A warrants 10,946 10,946 Series B warrants 28,750 28,750 Series C warrants 63,749 35,000 Warrants with no class designation 1,975 1,975 Total 105,420 76,671

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
SCHEDULE OF RIGHT USE OF ASSET	ROU is summarized below: SCHEDULE OF RIGHT USE OF ASSET June 30, 2022 June 30, 2021 Office lease $ 66,201 $ 48,662 Less: accumulated amortization (3,678 ) (48,662 ) Right-of-use asset, net $ 62,523 $ -
SCHEDULE OF OPERATING LEASE LIABILITY	Operating Lease liabilities are summarized below: SCHEDULE OF OPERATING LEASE LIABILITY June 30, 2022 June 30, 2021 Office lease $ 66,201 $ 48,662 Reduction of lease liability (3,277 ) (48,662 ) Less: office lease, current portion (20,605 ) - Long term portion of lease liability $ 42,319 $ -
SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS	Remaining future minimum lease payments under non-cancelable operating lease at June 30, 2022 are as follows: SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS Fiscal Year 2023 $ 24,894 Fiscal Year 2024 24,894 Fiscal Year 2025 20,745 Imputed interest (7,609 ) Total operating lease liability $ 62,924

DERIVATIVE FINANCIAL INSTRUME_2

DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Jun. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES	SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES June 30, 2022 June 30, 2021 Volatility 228 % 222 % Expected remaining term 0.01 0.01 Risk-free interest rate 1.28 % 0.05 % Expected dividend yield None None
SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS	SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS Balance at Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 151,262 $ — $ — $ 151,262 Total $ 151,262 $ — $ — $ 151,262 The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2021: Balance at Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Embedded conversion option liabilities $ 54,220 $ — $ — $ 54,220 Total $ 54,220 $ — $ — $ 54,220
SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE	The following is a roll forward for the years ended June 30, 2022 and 2021 of the fair value liability of price adjustable derivative instruments: SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE Fair Value of Liability for Derivative Instruments Balance at June 30, 2020 $ 177,009 Gain on debt extinguishment (130,975 ) Change in fair value included in statements of operations 8,186 Balance at June 30, 2021 54,220 Gain on debt extinguishment (2,069 ) Change in fair value included in statements of operations 99,111 Balance at June 30, 2022 $ 151,262

SCHEDULE OF TRANSLATION EXCHANG

SCHEDULE OF TRANSLATION EXCHANGE RATES (Details)	Jun. 30, 2022	Jun. 30, 2021
Property, Plant and Equipment [Line Items]
Foreign currency exchange rate, translation	0.6915	0.7500
Weighted Average [Member]
Property, Plant and Equipment [Line Items]
Foreign currency exchange rate, translation	0.7253	0.7473

SCHEDULE OF ACCUMULATED OTHER C

SCHEDULE OF ACCUMULATED OTHER COMPREHENSIVE INCOME LOSS (Details) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Accounting Policies [Abstract]
Beginning balance	$ 1,085,204	$ 1,267,671
Foreign currency translation, gain	149,345	182,467
Ending balance	$ 1,234,549	$ 1,085,204

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT ESTIMATED USEFUL LIVE (Details)	12 Months Ended
	Jun. 30, 2022
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant And equipment	5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property plant And equipment	7 years

SCHEDULE OF ANTI-DILUTIVE SECUR

SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) - shares	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	127,167,864	12,538,419
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	59	59
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	105,420	121,329
Unvested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	59	59
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	127,062,326	12,416,972

NATURE OF OPERATIONS AND SUMM_4

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES (Details Narrative) - USD ($)			3 Months Ended	12 Months Ended
	May 18, 2022	Nov. 17, 2020	Jun. 30, 2022	Jun. 30, 2022	Jun. 30, 2021	May 17, 2022
Property, Plant and Equipment [Line Items]
Reverse stock split		one-for-one thousand
Common stock, par value	$ 0.001		$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	3,000,000,000		3,000,000,000	3,000,000,000	3,000,000,000	1,000,000,000
New issuance, shares	3,001,500,005			56,799,716
Cash and cash equivalents			$ 0	$ 0	$ 0
Value added tax receivable			$ 2,342	2,342	4,341
Research and development expense, total				256,052	230,956
Tax credit				$ 54,977	113,415
Beneficial ownership conversion, description				Each holder of the notes has agreed to a 4.99% beneficial ownership conversion limitation (subject to certain noteholders’ ability to increase such limitation to 9.99% upon 60 days’ notice to the Company), and each note may not be converted during the first six-month period from the date of issuance.
beneficial ownership, rate				4.99%
2021 Securities Purchase Agreement [Member] | Note holders [Member]
Property, Plant and Equipment [Line Items]
Ownership, rate			9.99%	9.99%
Intercompany Loans [Member]
Property, Plant and Equipment [Line Items]
Foreign currency transaction, gain				$ 1,289,000	$ 1,005,000
Common Stock [Member]
Property, Plant and Equipment [Line Items]
Common stock, par value	$ 0.001
New issuance, shares			25,663,288	25,663,288	29,820
Common Stock [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Common stock, shares authorized	1,000,000,000
Common Stock [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Common stock, shares authorized	3,000,000,000
Preferred Stock [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Common stock, shares authorized	1,500,005

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 2,658,087	$ 2,025,947
Net cash used in operations	1,436,304	1,145,264
Working capital deficit	3,047,951
Stockholders' deficit	3,023,649	3,067,573	$ 3,641,425
Accumulated deficit	$ 61,557,893	$ 58,199,466

SCHEDULE OF PROPERTY PLANT AND

SCHEDULE OF PROPERTY PLANT AND EQUIPMENT (Details) - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Office equipment at cost	$ 28,623	$ 28,623
Less: Accumulated depreciation	(26,600)	(24,368)
Total property, plant, and equipment	$ 2,023	$ 4,255

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 1,993	$ 1,993

DUE TO FORMER DIRECTOR - RELA_2

DUE TO FORMER DIRECTOR - RELATED PARTY (Details Narrative) - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Due To Former Director - Related Party
Due to related parties, current	$ 30,746	$ 33,347

LOANS AND NOTES PAYABLE (Detail

LOANS AND NOTES PAYABLE (Details Narrative) - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Former Director [Member]
Defined Benefit Plan Disclosure [Line Items]
Loans payable	$ 51,171	$ 55,500

SCHEDULE OF CONVERTIBLE NOTES (

SCHEDULE OF CONVERTIBLE NOTES (Details) - USD ($)	Jun. 30, 2022	Jun. 30, 2021	Nov. 30, 2020
Debt Disclosure [Abstract]
Convertible notes and debenture	$ 644,980	$ 400,128
Unamortized discounts	(31,669)	(6,139)
Accrued interest	57,822	34,098	$ 416
Premium, net	313,127	196,496	$ 11,785
Convertible notes, net	$ 984,260	$ 624,583

CONVERTIBLE NOTES (Details Narr

CONVERTIBLE NOTES (Details Narrative)																																		1 Months Ended		12 Months Ended
	May 12, 2022 USD ($)	May 12, 2022 USD ($)	Apr. 12, 2022 USD ($)	Mar. 29, 2022 USD ($)	Mar. 07, 2022 USD ($)	Jan. 04, 2022 USD ($)	Dec. 07, 2021 USD ($)	Nov. 26, 2021 USD ($)	Oct. 21, 2021 USD ($)	Sep. 22, 2021 USD ($)	Aug. 19, 2021 USD ($)	Mar. 16, 2021 USD ($)	Jan. 05, 2021 USD ($)	Dec. 10, 2020 USD ($)	Dec. 02, 2020 USD ($)	Nov. 30, 2020 USD ($)	Sep. 16, 2020 shares	Sep. 09, 2020 shares	Mar. 25, 2020 USD ($)	Mar. 12, 2020 USD ($) Integer	Mar. 05, 2020 USD ($)	Feb. 19, 2020 USD ($)	Jan. 22, 2020 USD ($)	Jan. 13, 2020 USD ($)	Jan. 07, 2020 USD ($)	Oct. 03, 2019 USD ($)	Oct. 02, 2019 USD ($)	Sep. 04, 2019 USD ($)	Aug. 30, 2019 USD ($) $ / shares shares	Dec. 24, 2018 USD ($)	Aug. 29, 2018 USD ($)	Aug. 10, 2017 USD ($)	Aug. 10, 2017 USD ($) Integer	Apr. 30, 2020	Aug. 30, 2019 USD ($) $ / shares shares	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2020 USD ($)	Mar. 15, 2021 USD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2017 USD ($)
Short-Term Debt [Line Items]
Debt instrument face amount																$ 19,600																				$ 1,000	$ 95,000
Common stock trading volume, percent																																				4.99%
Debt instrument unamortized premium																11,785																				$ 313,127	196,496
Additional paid in capital																																				57,124,982	54,074,110
Embedded derivative, fair value of embedded derivative liability																																				151,262	54,220
Accrued interest																416																				57,822	34,098
Liabilities																																				3,105,300	3,080,674
Gains losses on extinguishment of debt																																				(17,503)	50,607
Original issue discount																																				31,669	6,139
Proceeds from convertible debt																																				766,500	325,000
Unissued shares conversion | shares																	24,427
Due to equity conversion																31,801
Original issue discounts amount																																				73,500	16,000
Amortization of debt discount																																				47,971	136,527
Conversion of Stock, Amount Converted																																				335,677	590,504
Two Convertible Notes [Member]
Short-Term Debt [Line Items]
Convetible notes																																				144,280
Accrued interest																																				$ 33,930
Two Convertible Notes [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Interest rate																																				15%
Two Convertible Notes [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Interest rate																																				18%
Auctus Fund, LLC [Member] | August 2019 Auctus Note [Member]
Short-Term Debt [Line Items]
Accrued interest																																				$ 716	39,536	$ 43,176
1800 Diagonal Lending [Member] | May 12, 2022 1800 Diagonal Note [Member]
Short-Term Debt [Line Items]
Accrued interest																																				4,700
ONE44 Capital LLC [Member] | March 29, 2022 Securities Purchase Agreement [Member]
Short-Term Debt [Line Items]
Accrued interest																																				2,873
August 29, 2018 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | August 2018 Eagle Note [Member]
Short-Term Debt [Line Items]
Debt instrument face amount																															$ 105,000
Maturity date																															Aug. 29, 2019
Interest rate																															8%
Debt default amount percentage																																		24%
December 24, 2018 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | December 2018 Eagle Note [Member]
Short-Term Debt [Line Items]
Debt instrument face amount																														$ 126,000
Maturity date																														Dec. 24, 2019
Interest rate																														8%
Debt default amount percentage																														24%				24%
Debt instrument principal payment																														$ 6,000
Debt original issue discount, rate																														10%
Percentage of outstanding shares of common stock																														4.99%
Debt instrument unamortized premium																																					357,688
Additional paid in capital																																					133,557
Convetible notes																																					0
December 24, 2018 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | December 2018 Eagle Note [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Common stock trading volume, percent																														60%
December 24, 2018 Securities Purchase Agreement [Member] | Eagle Equities, LLC [Member] | December 2018 Eagle Note [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Common stock trading volume, percent																														61%
December 24, 2018 Securities Purchase Agreement [Member] | Depository Trust Company [Member] | December 2018 Eagle Note [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Common stock trading volume, percent																														50%
December 24, 2018 Securities Purchase Agreement [Member] | Depository Trust Company [Member] | December 2018 Eagle Note [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Common stock trading volume, percent																														51%
August 10, 2017 Consulting Agreement [Member]
Short-Term Debt [Line Items]
Debt instrument face amount																																						8,500		$ 9,000
Maturity date																																Aug. 10, 2017	Aug. 10, 2019
Interest rate																																10%	10%
Debt default amount percentage																																	18%
Common stock trading volume, percent																																	65%
Convetible notes																																$ 310,000	$ 310,000
Debt conversion converted instrument																																	$ 750			1,000		500
Debt conversion, description | Integer																																	10
Accrued liabilities current and non current																																						5,248			$ 155,000	$ 155,000
Embedded derivative, fair value of embedded derivative liability																																578,212	$ 578,212
Accrued interest																																				8,000		22,168
August 10, 2017 Consulting Agreement [Member] | Settlement and Mutual Release Agreement [Member]
Short-Term Debt [Line Items]
Debt instrument face amount																																							$ 8,500
Convetible notes																																$ 79,000	$ 79,000				80,000		100,000
Debt conversion converted instrument																																					20,000
Accrued liabilities current and non current																																							25,000
Accrued interest																																				10,185	3,738		23,262
Liabilities																																							$ 56,762
Gains losses on extinguishment of debt																																					43,238
August 10, 2017 Consulting Agreement [Member] | Consultant [Member]
Short-Term Debt [Line Items]
Debt instrument face amount																																								161,000	140,000
Accrued interest																																								$ 19,418	$ 10,764
Securities Purchase Agreement [Member]
Short-Term Debt [Line Items]
Original issue discount																																				452,308	498,160
Amortization of debt discount																																				73,500	211,000
Securities Purchase Agreement [Member] | August 2019 Auctus Note [Member]
Short-Term Debt [Line Items]
Interest rate																													24%						24%
Securities Purchase Agreement [Member] | January 13, 2020 Ader Alef Note [Member]
Short-Term Debt [Line Items]
Debt instrument face amount																								$ 110,250													0	110,250
Maturity date																								Jan. 13, 2020
Interest rate																								8%
Debt default amount percentage																								24%
Debt instrument unamortized premium																																					59,365
Debt conversion converted instrument																								$ 100,000													110,250
Accrued interest																																					0	4,073
Original issue discount																								5,250
Legal fees																								$ 5,000
Debt conversion of accrued interest																																					7,493
Securities Purchase Agreement [Member] | January 13, 2020 Ader Alef Note [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt default amount percentage																								120%
Common stock trading volume, percent																								35%
Percentage of outstanding shares of common stock																								4.99%
Debt instrument description																								The conversion price for the January 13, 2020 Ader Alef Note during the first 6 months the January 13, 2020 Ader Alef Note was fixed at $2.50 and thereafter would be equal to a 35% discount of the lowest closing bid price (“Lowest Trading Price”) of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion, including the day upon which a Notice of Conversion was received. Notwithstanding the foregoing, Ader Alef was restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Ader Alef and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock which may be increased up to 9.99% upon 60 days prior written notice by the Ader Alef to the Company.
Securities Purchase Agreement [Member] | January 13, 2020 Ader Alef Note [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt default amount percentage																								150%
Percentage of outstanding shares of common stock																								9.99%
Securities Purchase Agreement [Member] | September 22, 2021 Geneva Roth [Member]
Short-Term Debt [Line Items]
Accrued interest																																					3,120
Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | January 22, 2020 GS Note [Member]
Short-Term Debt [Line Items]
Debt instrument face amount																							$ 58,000
Maturity date																							Jan. 22, 2021
Interest rate																							10%
Debt default amount percentage																							24%
Common stock trading volume, percent																							40%
Debt instrument unamortized premium																							$ 38,667
Additional paid in capital																																						38,667
Convetible notes																																					0
Debt conversion converted instrument																																					58,000
Original issue discount																							3,500
Legal fees																							2,500
Debt conversion of accrued interest																																					8,508
Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | January 22, 2020 GS Note [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Proceeds from convertible debt																							$ 52,000
Debt default amount percentage																							112%
Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | January 22, 2020 GS Note [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt default amount percentage																							130%
Securities Purchase Agreement [Member] | Auctus Fund, LLC [Member] | August 2019 Auctus Note [Member]
Short-Term Debt [Line Items]
Debt instrument face amount																												$ 550,000	$ 550,000						$ 550,000
Maturity date																													Aug. 30, 2020
Interest rate																													10%						10%
Debt default amount percentage																													24%
Common stock trading volume, percent																																			60%
Percentage of outstanding shares of common stock																													125%						4.99%
Debt instrument unamortized premium																													$ 366,667						$ 366,667	21,899	217,411	127,356
Convetible notes																																				0
Debt conversion converted instrument																																				32,848	326,117	191,035
Accrued interest																													$ 15,000						$ 15,000	0	0	486
Legal fees																												5,000
Proceeds from convertible debt																												505,000
Diligence fees																												$ 40,000
Debt instrument description																													Upon the holder’s election to convert accrued interest, default interest or any penalty amounts as stipulated, the Company may elect to pay those amounts in cash. The note may also be prepaid by the Company at any time between the date of issuance and August 13, 2020 at 135% multiplied by the sum of (a) the then outstanding principal amount plus (b) accrued and unpaid interest plus (c) default interests, if any.
Fair value adjustment of warrants																													$ 375,905
Securities Purchase Agreement [Member] | Auctus Fund, LLC [Member] | August 2019 Auctus Note [Member] | First Warrant [Member]
Short-Term Debt [Line Items]
Purchase of warrants | shares																													450						450
Warrant exercise price | $ / shares																													$ 2,250						$ 2,250
Securities Purchase Agreement [Member] | Auctus Fund, LLC [Member] | August 2019 Auctus Note [Member] | Second Warrant [Member]
Short-Term Debt [Line Items]
Purchase of warrants | shares																													300						300
Warrant exercise price | $ / shares																													$ 3,330						$ 3,330
Securities Purchase Agreement [Member] | Auctus Fund, LLC [Member] | August 2019 Auctus Note [Member] | Third Warrant [Member]
Short-Term Debt [Line Items]
Purchase of warrants | shares																													225						225
Warrant exercise price | $ / shares																													$ 4,500						$ 4,500
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member]
Short-Term Debt [Line Items]
Debt instrument face amount																9,600
Debt instrument unamortized premium																6,400
Unissued shares conversion | shares																	15,000
Due to equity conversion																16,000
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member] | October 3, 2019 GW Note [Member]
Short-Term Debt [Line Items]
Debt instrument face amount																										$ 108,000										65,280	65,280	65,280
Maturity date																										Oct. 03, 2019
Interest rate																										15%
Debt default amount percentage																										15%
Debt instrument principal payment																										$ 3,000
Debt instrument unamortized premium																										72,000												28,480
Debt conversion converted instrument																																						42,720
Accrued interest																																				$ 25,930	16,138	7,232
Original issue discount																										5,000
Proceeds from convertible debt																										$ 100,000
Debt instrument description																										The conversion price for the October 3, 2019 Crown Bridge Note shall be equal to a 40% discount of the lowest closing bid price (“Lowest Trading Price”) of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion, including the day upon which a Notice of Conversion is received. Notwithstanding the foregoing, Crown Bridge shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Crown Bridge and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock which may be increased up to 9.99% upon 60 days prior written notice by the Crown Bridge to the Company. The note is treated as stock settled debt under ASC 480 and accordingly the Company recorded a $72,000 put premium.
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member] | October 3, 2019 GW Note [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt default amount percentage																										110%
Percentage of outstanding shares of common stock																										4.99%
Securities Purchase Agreement [Member] | Crown Bridge Partners, LLC [Member] | October 3, 2019 GW Note [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt default amount percentage																										150%
Percentage of outstanding shares of common stock																										9.99%
Securities Purchase Agreement [Member] | GW Holdings Group, LLC [Member]
Short-Term Debt [Line Items]
Debt instrument face amount																																						101,000
Debt instrument unamortized premium																																					20,000	67,333
Convetible notes																																					0
Accrued interest																																					0	5,082
Securities Purchase Agreement [Member] | GW Holdings Group, LLC [Member] | October 1, 2019 GW Note [Member]
Short-Term Debt [Line Items]
Debt instrument face amount																											$ 131,000										30,000	30,000
Maturity date																											Oct. 01, 2020
Interest rate																											8%
Debt instrument principal payment																											$ 6,000
Accrued interest																																					3,877	1,776
Proceeds from convertible debt																											$ 125,000
Securities Purchase Agreement [Member] | GW Holdings Group, LLC [Member] | December Ten Two Thousand Twenty [Member]
Short-Term Debt [Line Items]
Debt instrument face amount														$ 131,000
Maturity date														Dec. 10, 2021
Interest rate														8%
Debt default amount percentage														24%
Debt instrument principal payment														$ 6,000
Debt instrument unamortized premium														174,666
Accrued interest																																					1,084
Proceeds from convertible debt														$ 125,000
Debt instrument description														The conversion price for the above GW Holdings notes was equal to a 40% discount of the lowest closing bid price (“Lowest Trading Price”) of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion, including the day upon which a Notice of Conversion was received. Notwithstanding the foregoing, GW Holdings shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by GW Holdings and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock which may be increased up to 9.99% upon 60 days prior written notice by the GW Holdings to the Company.
Securities Purchase Agreement [Member] | GW Holdings Group, LLC [Member] | December Ten Two Thousand Twenty [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt default amount percentage														110%
Percentage of outstanding shares of common stock														4.99%
Securities Purchase Agreement [Member] | GW Holdings Group, LLC [Member] | December Ten Two Thousand Twenty [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt default amount percentage														150%
Percentage of outstanding shares of common stock														9.99%
Securities Purchase Agreement [Member] | LG Capital Funding, LLC [Member]
Short-Term Debt [Line Items]
Debt instrument face amount																10,000
Debt instrument unamortized premium																5,385
Debt conversion converted instrument																416
Original issue discount																						$ 40,385
Due to equity conversion																$ 15,801
Securities Purchase Agreement [Member] | LG Capital Funding, LLC [Member] | February19 2020 LG Capital Note [Member]
Short-Term Debt [Line Items]
Debt instrument face amount																						$ 75,000															0	75,000
Maturity date																						Feb. 19, 2021
Interest rate																						8%
Common stock trading volume, percent																						24%
Debt instrument unamortized premium																																					40,385
Debt conversion converted instrument																																					75,000
Accrued interest																																					0	2,164
Original issue discount																						$ 3,750
Legal fees																						$ 2,500
Proceeds from convertible debt																			$ 71,250
Debt conversion of accrued interest																																					5,421
Unissued shares conversion | shares																		9,427
Securities Purchase Agreement [Member] | LG Capital Funding, LLC [Member] | February19 2020 LG Capital Note [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt default amount percentage																						112%
Percentage of outstanding shares of common stock																						9.99%
Debt instrument description																						The conversion price for the February 19, 2020 LG Capital Note during the first 6 months the February 19, 2020 LG Capital Note was fixed at $500 and thereafter was equal to a 35% discount of the lowest closing bid price (“Lowest Trading Price”) of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion, including the day upon which a Notice of Conversion was received. Notwithstanding the foregoing, LG Capital was restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by LG Capital and its affiliates, exceeds 9.99% of the outstanding shares of the Company’s common stock.
Securities Purchase Agreement [Member] | LG Capital Funding, LLC [Member] | February19 2020 LG Capital Note [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt default amount percentage																						135%
Securities Purchase Agreement [Member] | Geneva Roth Remark Holdings Inc [Member] | December 02 2020 Geneva Roth [Member]
Short-Term Debt [Line Items]
Debt instrument face amount															$ 78,000
Maturity date															Dec. 02, 2021
Interest rate															8%
Original issue discount															$ 3,000
Securities Purchase Agreement [Member] | Geneva Roth Remark Holdings Inc [Member] | January 5, 2021 Geneva Roth [Member]
Short-Term Debt [Line Items]
Debt instrument face amount													$ 68,500
Maturity date													Jan. 05, 2022
Interest rate													8%
Original issue discount													$ 3,500
Securities Purchase Agreement [Member] | Geneva Roth Remark Holdings Inc [Member] | March 16, 2021 Geneva Roth [Member]
Short-Term Debt [Line Items]
Debt instrument face amount												$ 63,500
Maturity date												Mar. 16, 2022
Interest rate												8%
Original issue discount												$ 3,500
Securities Purchase Agreement [Member] | Geneva Roth Remark Holdings Inc [Member] | August 19, 2021 Geneva Roth [Member]
Short-Term Debt [Line Items]
Debt instrument face amount											$ 103,750
Interest rate											8%
Securities Purchase Agreement [Member] | Geneva Roth Remark Holdings Inc [Member] | September 22, 2021 Geneva Roth [Member]
Short-Term Debt [Line Items]
Debt instrument face amount										$ 63,750
Maturity date										Sep. 22, 2022	Aug. 19, 2022
Interest rate										8%
Debt default amount percentage										35%
Debt instrument unamortized premium										$ 203,269
Original issue discount											$ 3,750
Debt default amount percentage										22%
Debt instrument description										The conversion price for the above Geneva Roth notes was equal to a 35% discount of the market price based on the average of the lowest three trading prices of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion. Notwithstanding the foregoing, Geneva Roth shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Geneva Roth and its affiliates, exceeds 9.99% of the outstanding shares of the Company’s common stock.
Securities Purchase Agreement [Member] | Geneva Roth Remark Holdings Inc [Member] | September 22, 2021 Geneva Roth [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt default amount percentage										110%
Percentage of outstanding shares of common stock										9.99%
Securities Purchase Agreement [Member] | Geneva Roth Remark Holdings Inc [Member] | September 22, 2021 Geneva Roth [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt default amount percentage										129%
Securities Purchase Agreement [Member] | 1800 Diagonal Lending [Member] | October Twenty One Two Thousand Twenty One [Member]
Short-Term Debt [Line Items]
Debt instrument face amount									$ 63,750
Maturity date									Oct. 21, 2022
Interest rate									8%
Debt issue costs									$ 3,750
Securities Purchase Agreement [Member] | 1800 Diagonal Lending [Member] | November Twenty Six Two Thousand Twenty One [Member]
Short-Term Debt [Line Items]
Debt instrument face amount								$ 53,750
Maturity date								Nov. 26, 2022
Interest rate								8%
Debt issue costs								$ 3,750
Securities Purchase Agreement [Member] | 1800 Diagonal Lending [Member] | January 4, 2022 Securities Purchase Agreement [Member]
Short-Term Debt [Line Items]
Debt instrument face amount						$ 63,750
Maturity date						Jan. 04, 2023
Interest rate						8%
Debt issue costs						$ 3,750
Securities Purchase Agreement [Member] | 1800 Diagonal Lending [Member] | March 7, 2022 [Member]
Short-Term Debt [Line Items]
Debt instrument face amount					$ 68,750
Maturity date					Mar. 07, 2023
Interest rate					8%
Debt issue costs					$ 3,750
Securities Purchase Agreement [Member] | 1800 Diagonal Lending [Member] | April Twelve Two Thousand And Twenty Two [Member]
Short-Term Debt [Line Items]
Debt instrument face amount			$ 68,750
Maturity date			Apr. 12, 2023
Interest rate			8%
Debt issue costs			$ 3,750
Securities Purchase Agreement [Member] | 1800 Diagonal Lending [Member] | May 12, 2022 1800 Diagonal Note [Member]
Short-Term Debt [Line Items]
Debt instrument face amount	$ 63,750	$ 63,750
Maturity date		May 12, 2023
Interest rate	8%	8%
Debt default amount percentage		35%
Percentage of outstanding shares of common stock																																				150%
Debt instrument unamortized premium	$ 205,962	$ 205,962
Debt default amount percentage		22%
Debt instrument description		The conversion price for the above 1800 Diagonal notes shall be equal to a 35% discount of the market price which means the average of the lowest three trading prices of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion. Notwithstanding the foregoing, 1800 Diagonal shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by 1800 Diagonal and its affiliates, exceeds 9.99% of the outstanding shares of the Company’s common stock.
Penalty amount																																				$ 1,000
Debt issue costs	$ 3,750
Securities Purchase Agreement [Member] | 1800 Diagonal Lending [Member] | May 12, 2022 1800 Diagonal Note [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt default amount percentage		110%
Securities Purchase Agreement [Member] | 1800 Diagonal Lending [Member] | May 12, 2022 1800 Diagonal Note [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt default amount percentage		129%
Percentage of outstanding shares of common stock		9.99%
Securities Purchase Agreement [Member] | ONE44 Capital LLC [Member] | December 7, 2021 Geneva Roth [Member]
Short-Term Debt [Line Items]
Debt instrument face amount							$ 170,000
Maturity date							Dec. 07, 2022
Interest rate							10%
Original issue discounts amount							$ 25,500
Securities Purchase Agreement [Member] | ONE44 Capital LLC [Member] | March 29, 2022 Securities Purchase Agreement [Member]
Short-Term Debt [Line Items]
Debt instrument face amount				$ 120,000																																235,700
Maturity date				Mar. 29, 2023
Interest rate				10%
Debt default amount percentage				65%
Debt instrument unamortized premium				$ 156,154																																29,238
Debt conversion converted instrument																																				54,300
Accrued interest																																				9,519
Debt default amount percentage				24%
Original issue discounts amount				$ 18,000
Debt principal increase percentage				20%
Securities Purchase Agreement [Member] | ONE44 Capital LLC [Member] | March 29, 2022 Securities Purchase Agreement [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt default amount percentage				120%
Percentage of outstanding shares of common stock				4.99%
Penalty amount				$ 250
Securities Purchase Agreement [Member] | ONE44 Capital LLC [Member] | March 29, 2022 Securities Purchase Agreement [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt default amount percentage				135%
Penalty amount				$ 500
January 7, 2020 Power Up Lending Group Securities Purchase Agreement [Member] | January 7, 2020 Power Up Note [Member]
Short-Term Debt [Line Items]
Debt instrument face amount																									$ 75,000
Maturity date																									Jan. 07, 2021
Interest rate																									8%
Legal fees																								$ 2,500
Prepayment penalty																								72,000
Diligence fees																								$ 500
March 12, 2020 Power Up Lending Group Securities Purchase Agreement [Member] | March 12, 2020 Power Up Note [Member]
Short-Term Debt [Line Items]
Debt instrument face amount																				$ 43,000																	0
Maturity date																				Mar. 12, 2021
Interest rate																				8%
Debt default amount percentage																				150%
Common stock trading volume, percent																				65%
Percentage of outstanding shares of common stock																				4.99%
Convetible notes																																					0
Debt conversion, description | Integer																				10
Embedded derivative, fair value of embedded derivative liability																				$ 422,557
Accrued interest																																					0
Legal fees																					$ 2,500
Debt default amount percentage																				22%
Prepayment penalty																					40,000
Diligence fees																					$ 500
Debt conversion, description																				The conversion price for the above Power Up notes was $3,050, subject to certain Market Price (as defined below) adjustment. If the Market Price was greater than or equal to $5,000, the conversion price was to be the greater of 65% of the Market Price (“Variable Conversion Price”) and $3,050. In the event Market Price was less than $5,000, the conversion price was to be the Variable Conversion Price. As defined in the note agreements, the “Market Price” was the average of the lowest three closing bid prices during the ten day trading period prior to and including the day the Company receives a notice of conversion from Power Up on the electronic quotation system or applicable principal securities exchange or trading market or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” during the ten prior trading days, including the day upon which the Company receives a notice of conversion from Power Up. Notwithstanding the foregoing, Power Up was restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by Power Up and its affiliates, exceeds 4.99% of the outstanding shares of the Company’s common stock.
Repayment in cash																																					43,000
Repayment of interest																																					1,816
Auctus Financing Agreement [Member]
Short-Term Debt [Line Items]
Debt instrument face amount																																				0	32,848	$ 358,965
GW Holdings Financing Agreement [Member] | December Ten Two Thousand Twenty [Member]
Short-Term Debt [Line Items]
Debt instrument face amount																																				90,000
Debt instrument unamortized premium																																				60,000
Accrued interest																																				7,885
Penalty amount																																				4,000
GW Holdings Financing Agreement [Member] | GW Holdings Group, LLC [Member] | October 1, 2019 GW Note [Member]
Short-Term Debt [Line Items]
Debt instrument unamortized premium																																					27,333
GW Holdings Financing Agreement [Member] | GW Holdings Group, LLC [Member] | December Ten Two Thousand Twenty [Member]
Short-Term Debt [Line Items]
Debt instrument face amount														$ 90,000																						0	41,000
Accrued interest														$ 4,636																						0
Geneva Roth Financing Agreement [Member] | September 22, 2021 Geneva Roth [Member]
Short-Term Debt [Line Items]
Debt instrument face amount																																				299,500	78,000
Accrued interest																																				11,980
Geneva Roth Financing Agreement [Member] | Geneva Roth Remark Holdings Inc [Member] | September 22, 2021 Geneva Roth [Member]
Short-Term Debt [Line Items]
Debt instrument face amount																																				0	132,000
Debt instrument unamortized premium																																				161,269	42,000
Accrued interest																																					$ 3,477
Sixth Street Financing Agreement [Member] | 1800 Diagonal Lending [Member] | May 12, 2022 1800 Diagonal Note [Member]
Short-Term Debt [Line Items]
Debt instrument face amount																																				265,000
Debt instrument unamortized premium																																				63,269
Debt conversion converted instrument																																				117,500
Accrued interest																																				$ 6,081

SCHEDULE OF INCOME TAX PROVISIO

SCHEDULE OF INCOME TAX PROVISION (Details) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Income tax (expense) benefit	$ (54,977)	$ (113,415)
UNITED STATES
Loss before Income taxes	(2,658,087)	(2,025,947)
Taxes under statutory US tax rates	(558,198)	(425,449)
Increase (decrease) in valuation allowance	339,334	1,146,001
Prior period adjustment		(1,063,710)
Foreign tax rate differential	(64,349)	(51,169)
Income tax rate change	272,008	392,767
Other	11,205	1,559
Income tax (expense) benefit

SCHEDULE OF DEFERRED TAX ASSETS

SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Warrant Derivative Liability	$ 7,403	$ 7,403
Accrued Expenses	363,873	342,464
Prepaid Investor Services	427,318	444,411
Non-cash interest	709,936	687,529
Intangibles (Intellectual Property and Patent Cost)	293,260	259,743
Deferred Rent	4,198	4,262
Formation Expense	6,553	6,815
Net Operating Loss carryforward	8,759,357	8,546,920
Foreign Exchange Loss (OCI)	(39,379)	(39,379)
Revalue of derivative liability	460,772	439,958
Stock Based Compensation	84,028	51,481
Total Deferred tax assets	11,077,318	10,751,607
R&D	(170,435)	(197,604)
Gain on extinguishment of debt	(259,470)	(277,614)
Capital Raising Costs	(352,981)	(321,291)
Total deferred tax liabilities	(782,886)	(796,509)
Net deferred tax assets	10,294,432	9,955,098
Valuation allowance	(10,294,432)	(9,955,098)
Net deferred tax assets

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)		12 Months Ended
	Mar. 27, 2020	Jun. 30, 2022	Jun. 30, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Tax benefit		$ 54,977	$ 113,415
Operating loss carryforwards		$ 10,200,000
Income tax rate		25%	26%
Tax benefit		$ (54,977)	$ (113,415)
Unrecognized tax benefits		0	0
Changes in unrecognized tax benefits		0	0
UNITED STATES
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Tax benefit
Operating loss carryforwards		10,183,947
Tax benefit
AUSTRALIA
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Tax benefit		0	0
Operating loss carryforwards		26,482,912
Tax benefit		0	$ 0
AUSTRALIA | Expire in 2024 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating loss carryforwards		7,200,000
AUSTRALIA | Not Expire [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating loss carryforwards		$ 3,000,000
CARES Act [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Income Tax Examination, Description	The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021.

SCHEDULE OF SHARE BASED COMPENS

SCHEDULE OF SHARE BASED COMPENSATION STOCK OPTIONS ACTIVITY (Details) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Equity [Abstract]
Number of Shares, Outstanding, Beginning balance	59	60
Weighted Average Price Per Share, Outstanding, Beginning balance	$ 13,730	$ 76,370
Number of Shares, Issued
Weighted Average Price Per Share, Issued
Number of Shares, Exercised
Weighted Average Price Per Share, Exercised
Number of Shares, Expired		(1)
Weighted Average Price Per Share, Expired		$ 3,750,000
Number of Shares, Outstanding, Ending balance	59	59
Weighted Average Price Per Share, Outstanding, Ending balance	$ 4,533	$ 13,730
Number of Shares, Exercisable, Ending balance	59
Weighted Average Price Per Share, Exercisable, Ending balance	$ 4,531
Weighted average remaining contractual term	6 years 10 months 17 days
Weighted average fair value of options granted during the period	0 years
Aggregate intrinsic value

SCHEDULE OF WARRANT ACTIVITY (D

SCHEDULE OF WARRANT ACTIVITY (Details) - USD ($)	12 Months Ended
	Jun. 30, 2022		Jun. 30, 2021
Equity [Abstract]
Number of Shares, Outstanding, Beginning balance	121,329		151,170
Weighted Average Price Per Share, Outstanding, Beginning balance	$ 179.63		$ 150
Number of Shares, Issued
Weighted Average Price Per Share, Issued
Number of Shares, Exercised	(15,909)		(29,841)
Weighted Average Price Per Share, Exercised	$ 42.86		$ 26.15
Number of Shares, Forfeited
Weighted Average Price Per Share, Forfeited
Number of Shares, Expired
Weighted Average Price Per Share, Expired
Number of Shares, Outstanding, Ending balance	105,420	[1]	121,329
Weighted Average Price Per Share, Outstanding, Ending balance	$ 200.27		$ 179.63
Number of Shares, Exercisable, Ending balance	76,671
Weighted Average Price Per Share, Exercisable, Ending balance	$ 275.37
Weighted average remaining contractual term	9 months 7 days
Aggregate intrinsic value
[1]The total warrants of 105,420

SCHEDULE OF WARRANT ACTIVITY _2

SCHEDULE OF WARRANT ACTIVITY (Details) (Parenthetical) - shares	Jun. 30, 2022		Jun. 30, 2021	Jun. 30, 2020
Equity [Abstract]
Total warrants	105,420	[1]	121,329	151,170
[1]The total warrants of 105,420

SCHEDULE OF WARRANT OUTSTANDING

SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE (Details) - shares	Jun. 30, 2022		Jun. 30, 2021	Jun. 30, 2020
Class of Stock [Line Items]
Number of warrants	105,420	[1]	121,329	151,170
Exercisable	76,671
Series A Warrants [Member]
Class of Stock [Line Items]
Number of warrants	10,946
Exercisable	10,946
Series B Warrants [Member]
Class of Stock [Line Items]
Number of warrants	28,750
Exercisable	28,750
Series C Warrants [Member]
Class of Stock [Line Items]
Number of warrants	63,749
Exercisable	35,000
Warrants With No Class Designation [Member]
Class of Stock [Line Items]
Number of warrants	1,975
Exercisable	1,975
[1]The total warrants of 105,420

STOCKHOLDERS_ DEFICIT (Details

STOCKHOLDERS’ DEFICIT (Details Narrative)																		1 Months Ended			2 Months Ended	3 Months Ended		4 Months Ended	12 Months Ended
	Aug. 02, 2022 USD ($)	Jul. 13, 2022 USD ($) $ / shares shares	Jul. 02, 2022 shares	Jun. 30, 2022 USD ($) $ / shares shares	May 18, 2022 $ / shares shares	Apr. 13, 2022 USD ($) $ / shares shares	Feb. 17, 2022 USD ($) $ / shares shares	Jan. 24, 2022 USD ($) $ / shares shares	Jan. 20, 2022 USD ($) $ / shares shares	Nov. 30, 2021 USD ($) $ / shares shares	Aug. 12, 2021 USD ($) $ / shares shares	Jul. 20, 2021 USD ($) $ / shares shares	Mar. 22, 2021 USD ($) $ / shares shares	Nov. 17, 2020	Sep. 16, 2020 shares	Apr. 03, 2020 $ / shares shares	Mar. 20, 2020 Integer $ / shares shares	Sep. 30, 2021 USD ($) $ / shares shares	Jun. 30, 2021 USD ($) $ / shares shares	May 31, 2019 USD ($) $ / shares shares	Sep. 14, 2022 USD ($) $ / shares shares	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2021 USD ($) $ / shares shares	Jun. 30, 2021 USD ($) $ / shares shares	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2021 USD ($) $ / shares shares	Aug. 31, 2022 USD ($)	Jul. 12, 2022 shares	Jun. 30, 2022 AUD ($) shares	May 17, 2022 shares	Aug. 12, 2021 AUD ($)	Jun. 30, 2021 AUD ($) shares	Nov. 30, 2020 USD ($)	Jun. 30, 2020 shares
Class of Stock [Line Items]
Common Stock, Par or Stated Value Per Share | $ / shares				$ 0.001	$ 0.001														$ 0.001			$ 0.001	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Common Stock, Shares Authorized | shares				3,000,000,000	3,000,000,000														3,000,000,000			3,000,000,000	3,000,000,000	3,000,000,000	3,000,000,000	3,000,000,000			3,000,000,000	1,000,000,000		3,000,000,000
[custom:NumberOfPreferredStockAuthorizedShares-0] | shares					1,500,005
Preferred stock, shares authorized | shares				1,500,005	3,001,500,005														1,500,005			1,500,005	1,500,005	1,500,005	1,500,005	1,500,005			1,500,005			1,500,005
Stockholders equity reverse stock split														one-for-one thousand (1:1,000)
Preferred stock, par value | $ / shares				$ 0.01															$ 0.01			$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01
Stock issued during period, value																									$ 99,285
Common stock value				$ 220,351															$ 14,056			$ 220,351	$ 14,056	$ 14,056	$ 220,351	$ 14,056
Stock issued during period | shares					3,001,500,005																				56,799,716
Proceeds from issuance of common stock																						99,285			$ 99,285
Subscription receivable				23,758																		23,758			23,758		$ 23,758
Principal amount				1,000															95,000			1,000	95,000	95,000	1,000	95,000							$ 19,600
Accrued interest				57,822															34,098			57,822	34,098	34,098	57,822	34,098							416
Unissued shares conversion | shares															24,427
Debt instrument unamortized premium				313,127															196,496			313,127	196,496	196,496	313,127	196,496							11,785
Equity conversion																																	$ 31,801
Accrued interest				8,000															3,000			8,000	3,000	3,000	8,000	3,000
Debt instrument fair value				28,572															178,368			28,572	178,368	178,368	28,572	178,368
Loss on extinguishment debt conversion				19,572															80,368			19,572	80,368	80,368	19,572	80,368
Derivative fair value				$ 2,069															$ 130,975			$ 2,069	$ 130,975	$ 130,975	2,069	130,975
Reclassification of put premium upon debt conversion																									$ 335,677	$ 590,504
Common stock, shares issued | shares				220,350,921															14,055,393			220,350,921	14,055,393	14,055,393	220,350,921	14,055,393			220,350,921			14,055,393
Stock issued during period value services																										$ 125,572
Share based compensation																									$ 72,513	82,872
Share price | $ / shares				$ 0.0037																		$ 0.0037			$ 0.0037
Accrued salaries current				$ 37,341															$ 101,250			$ 37,341	$ 101,250	$ 101,250	$ 37,341	101,250			$ 54,000			$ 135,000
Deemed dividend																									$ 700,340	$ 391,749
Restricted stock units, value | $ / shares
Unvested stock option expense																									$ 0
Stock options granted | shares																									0	0
Warrants exercisable | shares																									15,909	29,841
Proceeds from warrants exercise																									$ 625,001	$ 776,044
2019 Equity Incentive Plan [Member]
Class of Stock [Line Items]
Number of common shares reserved for future issuance | shares				234																		234			234				234
Series B Warrant [Member]
Class of Stock [Line Items]
Proceeds from issuance of warrants																									$ 625,000	$ 776,044
Warrants exercised | shares				15,625															19,375			15,625	19,375	19,375	15,625	19,375			15,625			19,375
Warrant exercise price | $ / shares				$ 40																		$ 40			$ 40
Series A And C Warrant [Member]
Class of Stock [Line Items]
Stock issued during period | shares																										4,199,979
Series A Warrants [Member]
Class of Stock [Line Items]
Warrant exercise price | $ / shares				284																		284			284
Warrants exercise price | $ / shares				200																		200			200
Alternate cashless warrant exercise price | $ / shares				$ 0.001																		$ 0.001			$ 0.001
Percentage of exercise price and market price																									70%
Prefunded Warrants [Member]
Class of Stock [Line Items]
Warrants exercised | shares				15,625															10,445			15,625	10,445	10,445	15,625	10,445			15,625			10,445
Series B Warrants [Member]
Class of Stock [Line Items]
Warrants exercised | shares																			19,375				19,375	19,375		19,375						19,375
20 Series A and 1 Series C Warrants [Member]
Class of Stock [Line Items]
Common stock, shares issued | shares																			4,199,979				4,199,979	4,199,979		4,199,979						4,199,979
2084 Series A Warrants [Member]
Class of Stock [Line Items]
Common stock, shares issued | shares				56,799,716																		56,799,716			56,799,716				56,799,716
Legal Services [Member]
Class of Stock [Line Items]
Shares issued price per share | $ / shares									$ 0.03
Stock issued during period shares for services | shares									666,667
Stock issued during period value services									$ 20,000
Share based compensation																									$ 20,000
Consultant [Member] | Consultant Services [Member]
Class of Stock [Line Items]
Shares issued price per share | $ / shares								$ 0.02
Stock issued during period shares for services | shares								2,274,224
Stock issued during period value services								$ 45,030
Share based compensation																									45,030
Consultant One [Member] | Consultant Services [Member]
Class of Stock [Line Items]
Shares issued price per share | $ / shares							$ 0.02
Stock issued during period shares for services | shares							1,148,326
Stock issued during period value services							$ 24,000
Share based compensation																									24,000
Consultant Two [Member] | Consultant Services [Member]
Class of Stock [Line Items]
Shares issued price per share | $ / shares						$ 0.0122
Stock issued during period shares for services | shares						3,833,683
Stock issued during period value services						$ 46,771
Share based compensation																									$ 46,771
Consultant Three [Member] | Consultant Services [Member]
Class of Stock [Line Items]
Shares issued price per share | $ / shares				$ 0.0037																		$ 0.0037			$ 0.0037
Stock issued during period shares for services | shares				12,270,958
Stock issued during period value services				$ 45,403
Share based compensation																									$ 45,403
Stock issued during period shares employee benefit plan | shares			12,270,958
Chief Executive Officer [Member]
Class of Stock [Line Items]
Restricted stock units, shares | shares																				78
Chief Scientific Officer [Member]
Class of Stock [Line Items]
Restricted stock units, shares | shares																				39
Subsequent Event [Member]
Class of Stock [Line Items]
Shares issued price per share | $ / shares		$ 0.002
Stock issued during period | shares		14,336,712																			264,492,661
Proceeds from issuance of common stock		$ 24,711
Debt instrument contractual conversion price | $ / shares																					$ 0.001
Principal amount																					$ 327,200
Accrued interest																					$ 22,330
Proceeds from warrants exercise	$ 50,000
Convertible Debt [Member]
Class of Stock [Line Items]
Stock issued during period | shares																									96,959,620	8,786,113
Proceeds from issuance of common stock																									$ 657,125	$ 1,239,075
Debt instrument contractual conversion price | $ / shares																			$ 0.13				$ 0.13	$ 0.13		$ 0.13
Principal amount				599,148															$ 1,018,867			$ 599,148	$ 1,018,867	$ 1,018,867	599,148	$ 1,018,867
Accrued interest				36,154															103,321			36,154	103,321	103,321	36,154	103,321
Conversion fees				$ 2,250															$ 16,500			$ 2,250	$ 16,500	$ 16,500	$ 2,250	$ 16,500
Common stock, shares issued | shares				7,326,007																		7,326,007			7,326,007				7,326,007
Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised																									$ 19,572
Convertible Debt [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Common stock, shares issued | shares																												7,326,007
Common Stock [Member]
Class of Stock [Line Items]
Common Stock, Par or Stated Value Per Share | $ / shares					$ 0.001
Stock issued during period, value																									$ 25,663
Shares issued price per share | $ / shares				$ 0.01															$ 0.10			$ 0.01	$ 0.10	$ 0.10	$ 0.01	$ 0.10
Stock issued during period | shares																						25,663,288			25,663,288	29,820
Reclassification of put premium upon debt conversion
Common stock, shares issued | shares				15,625															29,820			15,625	29,820	29,820	15,625	29,820			15,625			29,820
Stock issued during period shares for services | shares																							580,609	580,609		805,646
Stock issued during period value services																			$ 58,061							$ 806
Consulting expenses																										58,061
Warrants exercised | shares				15,625																		15,625			15,625				15,625
Common Stock [Member] | Legal Services [Member]
Class of Stock [Line Items]
Shares issued price per share | $ / shares											$ 0.05
Stock issued during period shares for services | shares											166,667
Stock issued during period value services											$ 7,883
Share based compensation																									$ 7,883
Common Stock [Member] | Consultant Services [Member]
Class of Stock [Line Items]
Common stock value							$ 24,000
Shares issued price per share | $ / shares							$ 0.02											$ 0.04
Stock issued during period shares for services | shares																		2,819,712
Stock issued during period value services																		$ 104,611
Share based compensation																									104,611
Stock issued during period shares employee benefit plan | shares							1,148,326
Common Stock [Member] | Bonus Payable [Member]
Class of Stock [Line Items]
Shares issued price per share | $ / shares											$ 0.03
Stock issued during period shares for services | shares											2,800,000
Stock issued during period value services											$ 87,920
Bonus payable				$ 84,000															84,000			$ 84,000	$ 84,000	$ 84,000	84,000	84,000
Share based compensation																									3,920
Common Stock [Member] | Consultant [Member]
Class of Stock [Line Items]
Shares issued price per share | $ / shares													$ 0.30
Stock issued during period shares for services | shares													225,037
Stock issued during period value services													$ 67,511
Consulting expenses																										67,511
Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Restricted stock units, shares | shares																				117
Restricted stock units, value | $ / shares																				$ 4,250
Fair value granted, shares																				$ 497,240
Unrecognized restricted stock units expense																									248,620
Restricted stock units not yet vested, shares				$ 248,620															$ 248,620			$ 248,620	$ 248,620	$ 248,620	$ 248,620	$ 248,620
Unvested Restricted Stock Units [Member]
Class of Stock [Line Items]
Unvested restricted stock units | shares				59																		59			59				59
Maximum [Member] | Convertible Debt [Member]
Class of Stock [Line Items]
Debt instrument contractual conversion price | $ / shares				$ 0.04															$ 2			$ 0.04	$ 2	$ 2	$ 0.04	$ 2
Maximum [Member] | Common Stock [Member]
Class of Stock [Line Items]
Common Stock, Shares Authorized | shares					3,000,000,000
Minimum [Member] | Convertible Debt [Member]
Class of Stock [Line Items]
Debt instrument contractual conversion price | $ / shares				$ 0.01															$ 0.03			$ 0.01	$ 0.03	$ 0.03	$ 0.01	$ 0.03
Minimum [Member] | Common Stock [Member]
Class of Stock [Line Items]
Common Stock, Shares Authorized | shares					1,000,000,000
Common Stock Purchase Agreement [Member] | Dutchess [Member]
Class of Stock [Line Items]
Agreement term										36 months
Lowest trading price										92%
Percentage of average daily trading volume										300%
Common stock value										$ 250,000
Deferred offering cost				$ 20,000																		$ 20,000			$ 20,000
Common Stock Purchase Agreement [Member] | Dutchess [Member] | Restricted Stock [Member]
Class of Stock [Line Items]
Common stock value										$ 20,000
Restricted stock units, shares | shares										1,000,000
Shares issued price per share | $ / shares										$ 0.02
Common Stock Purchase Agreement [Member] | Dutchess [Member] | Maximum [Member]
Class of Stock [Line Items]
Stock issued during period, value										$ 5,000,000
Underlying Financing Agreements [Member]
Class of Stock [Line Items]
Number of common shares reserved for future issuance | shares				730,181,169																		730,181,169			730,181,169				730,181,169
Nathanielsz Cancellation Agreement [Member]
Class of Stock [Line Items]
Percentage of bonus of annual base salary											200%
Cancellation Agreement [Member] | Dr. Kenyon [Member]
Class of Stock [Line Items]
Share based compensation																									$ 4,788
Accrued salaries current											$ 102,600
Cancellation Agreement [Member] | Dr. Kenyon [Member]
Class of Stock [Line Items]
Common stock value											$ 107,388
Shares issued price per share | $ / shares											$ 0.03
Stock issued during period shares employee benefit plan | shares											3,420,000
Adjustments to additional paid in capital stock issued issuance costs																									102,600
Director Agreement [Member] | Josef Zelinger [Member]
Class of Stock [Line Items]
Common stock value																			$ 87,920				$ 87,920	$ 87,920		$ 87,920
Stock issued during period | shares																										2,800,000
Share based compensation																									3,920
Share price | $ / shares																			$ 0.03				$ 0.03	$ 0.03		$ 0.03
Adjustments to additional paid in capital stock issued issuance costs																									84,000
Accrued salaries current											$ 184																				$ 250
Accrued liabilities																			$ 84,000				$ 84,000	$ 84,000		$ 84,000
Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Equity purchase agreement description																the Company closed on a transaction related to a Securities Purchase Agreement (the “Securities Purchase Agreement”) entered into on March 30, 2020, whereby an investor purchased from the Company, 7,500 units, each consisting of (i) 1.5 shares of the Company’s common stock, or pre-funded warrants upon Investor’s election due to the 4.99% blocker provision and (ii) 1.5 warrants to purchase one share of Common Stock (“Series A Warrants”, and collectively with the Common Stock the “Units”).
Securities Purchase Agreement [Member] | Prefunded Warrants [Member]
Class of Stock [Line Items]
Warrants exercised | shares																10,445
Warrant exercise price | $ / shares																$ 0.10
Mr. Nathanielsz [Member]
Class of Stock [Line Items]
Share based compensation																									8,299
Adjustments to additional paid in capital stock issued issuance costs																									$ 177,840
Mr. Nathanielsz [Member] | Nathanielsz Cancellation Agreement [Member]
Class of Stock [Line Items]
Common stock value												$ 186,139
Percentage of bonus of annual base salary												78%
Officers compensation												$ 177,840
Debt conversion converted instrument shares issued | shares												5,928,000
Share price | $ / shares												$ 0.03
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized | shares				500,000															500,000			500,000	500,000	500,000	500,000	500,000			500,000			500,000		500,000
Preferred stock, par value | $ / shares				$ 0.01															$ 0.01			$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01
Preferred stock shares issued | shares				500,000															500,000			500,000	500,000	500,000	500,000	500,000			500,000			500,000
Preferred stock shares outstanding | shares				500,000															500,000			500,000	500,000	500,000	500,000	500,000			500,000			500,000
Stock issued during period, shares | shares				0															0			0	0	0	0	0			0			0
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized | shares				5															5			5	5	5	5	5			5			5
Preferred stock, par value | $ / shares				$ 0.01															$ 0.01			$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01
Preferred stock shares issued | shares				1															1			1	1	1	1	1			1			1
Preferred stock shares outstanding | shares				1															1			1	1	1	1	1			1			1
Stock issued during period, shares | shares				0															0			0	0	0	0	0			0			0
Series B Preferred Stock [Member] | Nathanielsz [Member]
Class of Stock [Line Items]
Beneficial ownership shares | shares				1																		1			1				1
Prefunded Warrants [Member]
Class of Stock [Line Items]
Warrants exercised | shares																			10,445				10,445	10,445		10,445						10,445
Series A Warrant [Member]
Class of Stock [Line Items]
Warrants exercise price | $ / shares				$ 200																		$ 200			$ 200
Series B Warrants [Member] | Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Warrants exercised | shares																63,750	3,750
Warrant exercise price | $ / shares																	$ 40
Warrants term																	3 years
Series B Warrants [Member] | Securities Purchase Agreement [Member] | Investor [Member]
Class of Stock [Line Items]
Warrants exercised | shares																	63,750
Warrants exercisable | shares																	37,500
Trading days | Integer																	10
Series B Warrants [Member] | Securities Purchase Agreement [Member] | Holder [Member]
Class of Stock [Line Items]
Stock issued during period | shares																	3,750
Series C Warrants [Member] | Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Warrants exercised | shares																63,750
Series C Warrants [Member] | Securities Purchase Agreement [Member] | Investor [Member]
Class of Stock [Line Items]
Warrants exercised | shares																	63,750
Warrant exercise price | $ / shares																	$ 200
Warrants term																	3 years
Series A Warrants [Member] | Securities Purchase Agreement [Member] | Investor [Member]
Class of Stock [Line Items]
Warrants exercised | shares																	11,250
Warrant exercise price | $ / shares																	$ 200
Warrants term																	3 years
Warrant description																	the Series A Warrants contain a provision for a cashless conversion at the Holder’s option should the trading price of the Common Stock fall below $200 per share calculated based on the difference between the exercise price of the Series A Warrant and 70% of the Market Price, as defined therein (the” Alternate Cashless Exercise”). The Alternate Cashless Exercise price is $0.001.

SCHEDULE OF RIGHT USE OF ASSET

SCHEDULE OF RIGHT USE OF ASSET (Details) - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Office lease	$ 66,201	$ 48,662
Less: accumulated amortization	(3,678)	(48,662)
Right-of-use asset, net	$ 62,523

SCHEDULE OF OPERATING LEASE LIA

SCHEDULE OF OPERATING LEASE LIABILITY (Details) - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Office lease	$ 66,201	$ 48,662
Reduction of lease liability	(3,277)	(48,662)
Less: office lease, current portion	(20,605)
Long term portion of lease liability	$ 42,319

SCHEDULE OF FUTURE MINIMUM LEAS

SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS (Details)	Jun. 30, 2022 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Fiscal Year 2023	$ 24,894
Fiscal Year 2024	24,894
Fiscal Year 2025	20,745
Imputed interest	(7,609)
Total operating lease liability	$ 62,924

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Narrative)

1 Months Ended

3 Months Ended

4 Months Ended

12 Months Ended

Feb. 17, 2022 USD ($) $ / shares shares

Oct. 02, 2021 USD ($)

Mar. 22, 2021 USD ($)

Oct. 02, 2020 USD ($)

Oct. 02, 2020 EUR (€)

Sep. 26, 2019 USD ($)

Sep. 13, 2018 USD ($)

Sep. 13, 2018 EUR (€)

May 05, 2016 USD ($)

May 05, 2016 AUD ($)

Sep. 30, 2022 USD ($)

Sep. 30, 2022 EUR (€)

Dec. 31, 2021 USD ($)

Dec. 31, 2021 EUR (€)

Sep. 30, 2021 $ / shares shares

May 31, 2021

Mar. 31, 2021 USD ($)

Mar. 31, 2021 EUR (€)

Nov. 30, 2020 EUR (€)

May 31, 2017 USD ($)

Jun. 30, 2012

Jun. 30, 2021 USD ($) $ / shares shares

Jun. 30, 2021 USD ($) $ / shares shares

Jun. 30, 2022 USD ($) $ / shares

Jun. 30, 2021 USD ($) $ / shares shares

Jun. 30, 2021 EUR (€) shares

Jun. 30, 2019 USD ($)

Jun. 30, 2019 EUR (€)

Sep. 14, 2022 USD ($)

Jul. 13, 2022 $ / shares

May 04, 2022 USD ($)

Mar. 15, 2021 USD ($)

Nov. 30, 2020 USD ($)

Product Liability Contingency [Line Items]

Total litigation penalty amount

$ 30,000

Liabilities

$ 3,080,674

$ 3,080,674

3,105,300

$ 3,080,674

Interest Payable

34,098

34,098

57,822

34,098

$ 416

Payments for Rent

28,366

28,112

Operating Lease, Right-of-Use Asset

$ 62,523

Weighted average remaining lease term

2 years 9 months 7 days

Payment for services

24,043

€ 28,493

$ 36,117

€ 31,754

Royalties percentage

2%

2%

Common stock value

$ 14,056

$ 14,056

$ 220,351

14,056

Common Stock [Member]

Product Liability Contingency [Line Items]

Total professional fees owed

$ 58,061

Stock Issued During Period, Shares, Issued for Services | shares

580,609

580,609

805,646

805,646

Share issued price per share | $ / shares

$ 0.10

$ 0.10

$ 0.01

$ 0.10

Consultant Services [Member] | Common Stock [Member]

Product Liability Contingency [Line Items]

Stock Issued During Period, Shares, Issued for Services | shares

2,819,712

Stock issued during period shares employee benefit plan | shares

1,148,326

Share issued price per share | $ / shares

$ 0.02

$ 0.04

Common stock value

$ 24,000

Subsequent Event [Member]

Product Liability Contingency [Line Items]

Interest Payable

$ 22,330

Share issued price per share | $ / shares

$ 0.002

Accounting Standards Update 2016-02 [Member]

Product Liability Contingency [Line Items]

Lessee, Operating Lease, Description

Such lease expired in May 2021 and was renewed for another one-year term from May 2021 to May 2022

Operating Lease, Right-of-Use Asset

$ 66,201

Operating Lease, Liability

$ 66,201

Operating Lease, Weighted Average Discount Rate, Percent

8%

From 2012 through the 2014 [Member]

Product Liability Contingency [Line Items]

Total litigation penalty amount

$ 10,000

Regal Consulting, LLC [Member]

Product Liability Contingency [Line Items]

Loss Contingency, Damages Sought, Value

$ 400,000

Stock Issued During Period, Shares, Issued for Services | shares

60

60

Regal Consulting, LLC [Member] | 2017 Note [Member]

Product Liability Contingency [Line Items]

Convertible Debt

$ 106,500

Total litigation penalty amount

$ 100,000

University of Jaen [Member]

Product Liability Contingency [Line Items]

Payment for services

$ 30,268

€ 25,837

Settlement Agreement [Member]

Product Liability Contingency [Line Items]

Gain from settlement of debt

$ 43,238

Liabilities

$ 56,762

Remaining principal amount

8,500

Interest Payable

23,262

Accrued Liabilities

25,000

Settlement and Mutual Release Agreement [Member] | Regal Consulting, LLC [Member]

Product Liability Contingency [Line Items]

Convertible Debt

$ 100,000

Royalty Agreement Terms [Member]

Product Liability Contingency [Line Items]

Operating leases income statement revenue percentage

2%

License Agreement Terms [Member]

Product Liability Contingency [Line Items]

Operating leases income statement revenue percentage

5%

New Five-Year Operating Lease Agreement [Member]

Product Liability Contingency [Line Items]

Lessee, Operating Lease, Term of Contract

5 years

5 years

Payments for Rent

$ 2,469

$ 3,606

Lessee, Operating Lease, Description

The initial rental amount was $3,000 AUD and subject to 3% yearly escalation.

The initial rental amount was $3,000 AUD and subject to 3% yearly escalation.

Three Year Operating Lease Agreement [Member]

Product Liability Contingency [Line Items]

Payments for Rent

$ 2,176

$ 3,000

1-Year Collaboration Agreement [Member]

Product Liability Contingency [Line Items]

Payment for services

$ 59,508

€ 52,000

2-Year Collaboration Agreement [Member]

Product Liability Contingency [Line Items]

Payment for services

$ 35,145

€ 30,000

$ 45,775

€ 40,000

2-Year Collaboration Agreement [Member] | Installment 1 [Member]

Product Liability Contingency [Line Items]

Payment for services | €

€ 5,000

2-Year Collaboration Agreement [Member] | Installment 2 [Member]

Product Liability Contingency [Line Items]

Payment for services

$ 5,858

€ 5,000

2-Year Collaboration Agreement [Member] | Installment 3 [Member]

Product Liability Contingency [Line Items]

Payment for services

$ 11,715

€ 10,000

2-Year Collaboration Agreement [Member] | Installment 4 [Member] | Subsequent Event [Member]

Product Liability Contingency [Line Items]

Payment for services

$ 11,715

€ 10,000

Consulting Agreement [Member]

Product Liability Contingency [Line Items]

Payment for consulting

$ 7,000

Consulting Agreement [Member] | Consultant Services [Member]

Product Liability Contingency [Line Items]

Share based compensation

$ 24,000

Foley Shechter [Member]

Product Liability Contingency [Line Items]

Professional fees

$ 151,031

Foley Shechter [Member] | Settlement Agreement [Member]

Product Liability Contingency [Line Items]

Total professional fees owed

$ 51,032

Settlement amount

51,032

Total accounts payable and accrued expenses

$ 142,660

Gain from settlement of debt

$ 92,556

RELATED PARTY TRANSACTIONS AN_2

RELATED PARTY TRANSACTIONS AND BALANCES (Details Narrative)

1 Months Ended

12 Months Ended

Aug. 02, 2022 USD ($)

Aug. 02, 2022 AUD ($)

Aug. 02, 2022 USD ($)

Aug. 02, 2022 AUD ($)

May 04, 2022 USD ($)

May 04, 2022 AUD ($)

Aug. 12, 2021 USD ($) shares

Jul. 13, 2020 AUD ($)

May 14, 2019 USD ($) $ / shares shares

May 14, 2019 AUD ($) shares

Mar. 16, 2018 USD ($)

Mar. 16, 2018 AUD ($)

Feb. 01, 2018 USD ($)

Feb. 01, 2018 AUD ($)

May 05, 2016 USD ($)

May 05, 2016 AUD ($)

Feb. 25, 2016 USD ($)

Feb. 25, 2016 AUD ($)

Feb. 25, 2015 AUD ($)

May 31, 2021

May 31, 2019 shares

Jun. 30, 2022 USD ($) $ / shares shares

Jun. 30, 2022 AUD ($) shares

Jun. 30, 2021 USD ($) $ / shares shares

Jun. 30, 2021 AUD ($) shares

Jun. 30, 2020 USD ($)

Jun. 30, 2020 AUD ($)

Jun. 30, 2019 USD ($)

Jun. 30, 2019 AUD ($)

Jun. 30, 2022 AUD ($)

Jun. 30, 2021 AUD ($)

May 05, 2016 AUD ($)

Related Party Transaction [Line Items]

Due to related parties | $

$ 30,746

$ 33,347

Payments for Rent | $

28,366

$ 28,112

Bonus payable

$ 99,691

$ 144,166

Exercise price | $ / shares

Granted exercise price | $ / shares

Accrued salaries

$ 37,341

$ 101,250

$ 54,000

$ 135,000

Chief Executive Officer [Member]

Related Party Transaction [Line Items]

Payments form related party

$ 221,890

$ 136,606

$ 202,620

$ 64,377

$ 90,000

Bonus payable amount

137,120

200,000

Remaining bonus amount

125,386

181,324

$ 178,256

$ 260,000

Bonus payable

166,418

$ 422,610

$ 280,726

$ 407,380

Restricted stock shares of common stock

78

Three Year Operating Lease Agreement [Member]

Related Party Transaction [Line Items]

Payments for Rent

$ 2,176

$ 3,000

Nathanielsz Employment Agreement [Member]

Related Party Transaction [Line Items]

Expired date

Feb. 25, 2019

Annual salary

$ 25,000

$ 205,680

$ 300,000

Percentage of pension of monthly salary

9.50%

9.50%

Nathanielsz Employment Agreement [Member] | Maximum [Member]

Related Party Transaction [Line Items]

Annual salary

$ 414,900

$ 600,000

$ 274,240

$ 400,000

Percentage of bonus of annual base salary

200%

200%

Nathanielsz Employment Agreement [Member] | Minimum [Member]

Related Party Transaction [Line Items]

Annual salary

$ 276,600

$ 400,000

$ 205,680

$ 300,000

Mrs. Nathanielsz [Member] | Chief Executive Officer [Member]

Related Party Transaction [Line Items]

Bonus payable | $

$ 316,957

Employment Agreement [Member]

Related Party Transaction [Line Items]

Restricted stock unit shares upon vest

39

39

Employment Agreement [Member] | Initial Nathanielsz RSUs [Member]

Related Party Transaction [Line Items]

Restricted stock shares of common stock

39

39

Employment Agreement [Member] | Additional Nathanielsz RSUs [Member]

Related Party Transaction [Line Items]

Restricted stock unit issuable

39

39

Employment Agreement [Member] | Additional Nathanielsz RSUs [Member]

Related Party Transaction [Line Items]

Grand date fair value, per share | $ / shares

$ 7.80

Gross proceeds from equity financing | $

$ 4,000,000

Services Agreement [Member]

Related Party Transaction [Line Items]

Restricted stock unit issuable

20

20

20

20

Services Agreement [Member] | Initial Kenyon RSUs [Member]

Related Party Transaction [Line Items]

Restricted stock shares of common stock

20

20

Services Agreement [Member] | Additional Kenyon RSUs [Member]

Related Party Transaction [Line Items]

Restricted stock shares of common stock

20

20

Gross proceeds from equity financing | $

$ 4,000,000

Restricted stock unit shares upon vest

5

5

Accounting Standards Update 2016-02 [Member]

Related Party Transaction [Line Items]

Operating lease, description

Such lease expired in May 2021 and was renewed for another one-year term from May 2021 to May 2022

North Horizon Pty Ltd [Member]

Related Party Transaction [Line Items]

Lessee, operating lease, term of contract

5 years

5 years

Operating leases rent expense, minimum rentals

$ 28,325

39,600

Goods and service tax

2,575

$ 3,600

Payments for Rent

$ 84,452

$ 122,129

$ 64,597

$ 86,129

North Horizon Pty Ltd [Member] | Three Year Operating Lease Agreement [Member]

Related Party Transaction [Line Items]

Lessee, operating lease, term of contract

3 years

3 years

Payments for Rent

$ 2,176

$ 3,000

Former Director [Member]

Related Party Transaction [Line Items]

Loans from related party | $

51,171

55,500

Due to related parties | $

30,746

33,347

Nathanielsz [Member] | North Horizon Pty Ltd [Member]

Related Party Transaction [Line Items]

Operating leases, future minimum payments due

$ 141,629

$ 198,000

Mrs. Nathanielsz [Member]

Related Party Transaction [Line Items]

Annual salary

$ 80,904

$ 120,000

Payments form related party

$ 5,577

$ 7,689

$ 34,476

$ 46,135

James Nathanielsz [Member]

Related Party Transaction [Line Items]

Payments form related party

$ 3,205

$ 4,481

Mr. Nathanielsz [Member] | Board of Directors [Member]

Related Party Transaction [Line Items]

Officers compensation

$ 177,840

$ 240,000

$ 315,376

$ 460,000

Debt conversion, converted instrument, shares issued

5,928,000

Mr. Nathanielsz [Member] | Board of Directors [Member] | Subsequent Event [Member]

Related Party Transaction [Line Items]

Officers compensation

$ 96,810

$ 140,000

Mr. Nathanielsz [Member] | Board of Directors [Member] | AUD Currency [Member]

Related Party Transaction [Line Items]

Bonus granted percentage

60%

Mr. Nathanielsz [Member] | Employment Agreement [Member]

Related Party Transaction [Line Items]

Annual salary | $

$ 400,000

Agreement term

3 years

3 years

Agreement renewal term

1 year

1 year

Option purchase shares

39

39

Exercise price | $ / shares

$ 4,675

Market price

110%

110%

Granted exercise price | $ / shares

$ 4,250

Options vested, description

The Nathanielsz Options have a term of 10 years from the date of grant. 1/3rd of the Nathanielsz Options shall vest every successive one-year anniversary following the Effective Date, provided, that on each such vesting date Mr. Nathanielsz is employed by the Company and subject to the other provisions of the Employment Agreement. The Initial Nathanielsz RSUs shall vest on the one-year anniversary of the Effective Date, subject to Mr. Nathanielsz’s continued employment with the Company through such vesting date. The Additional Nathanielsz RSUs will vest as follows, subject to Mr. Nathanielsz’s continued employment with the Company through the applicable vesting date: (i) 7.80 of the Additional Nathanielsz RSUs shall vest upon the Company submitting Clinical Trial Application (the “CTA”) for PRP, the Company’s lead product candidate (“PRP”), for a First-In-Human study for PRP (the “Study”) in an applicable jurisdiction to be selected by the Company, (ii) 7.80 of the Additional Nathanielsz RSUs shall vest upon the CTA being approved in an applicable jurisdiction, (iii) 7.80 of the Additional RSUs shall vest upon the Company completing an equity financing in the amount of at least $4,000,000 in gross proceeds, (iv) 7.80 of the Additional Nathanielsz RSUs shall vest upon the shares of the Company’s Common Stock being listed on a senior stock exchange (NYSE, NYSEMKT or NASDAQ), and (v) the remaining 7.80 of the Additional Nathanielsz RSUs shall vest upon the Company enrolling its first patient in the Study.

The Nathanielsz Options have a term of 10 years from the date of grant. 1/3rd of the Nathanielsz Options shall vest every successive one-year anniversary following the Effective Date, provided, that on each such vesting date Mr. Nathanielsz is employed by the Company and subject to the other provisions of the Employment Agreement. The Initial Nathanielsz RSUs shall vest on the one-year anniversary of the Effective Date, subject to Mr. Nathanielsz’s continued employment with the Company through such vesting date. The Additional Nathanielsz RSUs will vest as follows, subject to Mr. Nathanielsz’s continued employment with the Company through the applicable vesting date: (i) 7.80 of the Additional Nathanielsz RSUs shall vest upon the Company submitting Clinical Trial Application (the “CTA”) for PRP, the Company’s lead product candidate (“PRP”), for a First-In-Human study for PRP (the “Study”) in an applicable jurisdiction to be selected by the Company, (ii) 7.80 of the Additional Nathanielsz RSUs shall vest upon the CTA being approved in an applicable jurisdiction, (iii) 7.80 of the Additional RSUs shall vest upon the Company completing an equity financing in the amount of at least $4,000,000 in gross proceeds, (iv) 7.80 of the Additional Nathanielsz RSUs shall vest upon the shares of the Company’s Common Stock being listed on a senior stock exchange (NYSE, NYSEMKT or NASDAQ), and (v) the remaining 7.80 of the Additional Nathanielsz RSUs shall vest upon the Company enrolling its first patient in the Study.

Option term

10 years

10 years

Dr. Kenyon [Member] | Services Agreement [Member]

Related Party Transaction [Line Items]

Agreement term

3 years

3 years

Agreement renewal term

1 year

1 year

Option purchase shares

20

20

Exercise price | $ / shares

$ 4,250

Market price

100%

100%

Options vested, description

The Kenyon Options have a term of 10 years from the date of grant. 1/3rd of the Kenyon Options shall vest every successive one-year anniversary following the Effective Date, provided, that on each such vesting date Dr. Kenyon is employed by the Company and subject to the other provisions of the Services Agreement. The Initial Kenyon RSUs shall vest on the one-year anniversary of the Effective Date, subject to Dr. Kenyon’s continued employment with the Company through such vesting date. The Additional Kenyon RSUs will vest as follows, subject to Dr. Kenyon’s continued employment with the Company through the applicable vesting date: (i) 5 of the Additional Kenyon RSUs shall vest upon the Company submitting the CTA for PRP for the Study in an applicable jurisdiction to be selected by the Company, (ii) 5 of the Additional Kenyon RSUs shall vest upon the Company completing an equity financing in the amount of at least $4,000,000 in gross proceeds, (iii) 5 of the Additional Kenyon RSUs shall vest upon the shares of the Company’s Common Stock being listed on a senior stock exchange (NYSE, NYSEMKT or NASDAQ), and (iv) the remaining 5 of the Additional Kenyon RSUs shall vest upon the Company enrolling its first patient in the Study.

The Kenyon Options have a term of 10 years from the date of grant. 1/3rd of the Kenyon Options shall vest every successive one-year anniversary following the Effective Date, provided, that on each such vesting date Dr. Kenyon is employed by the Company and subject to the other provisions of the Services Agreement. The Initial Kenyon RSUs shall vest on the one-year anniversary of the Effective Date, subject to Dr. Kenyon’s continued employment with the Company through such vesting date. The Additional Kenyon RSUs will vest as follows, subject to Dr. Kenyon’s continued employment with the Company through the applicable vesting date: (i) 5 of the Additional Kenyon RSUs shall vest upon the Company submitting the CTA for PRP for the Study in an applicable jurisdiction to be selected by the Company, (ii) 5 of the Additional Kenyon RSUs shall vest upon the Company completing an equity financing in the amount of at least $4,000,000 in gross proceeds, (iii) 5 of the Additional Kenyon RSUs shall vest upon the shares of the Company’s Common Stock being listed on a senior stock exchange (NYSE, NYSEMKT or NASDAQ), and (iv) the remaining 5 of the Additional Kenyon RSUs shall vest upon the Company enrolling its first patient in the Study.

Option term

10 years

10 years

Dr. Kenyon [Member] | Cancellation Agreement [Member]

Related Party Transaction [Line Items]

Debt conversion, converted instrument, shares issued

3,420,000

Cancellation of accrued salary | $

$ 102,600

Dr Kenyon [Member] | Services Agreement [Member]

Related Party Transaction [Line Items]

Annual salary | $

$ 54,000

CONCENTRATIONS AND RISKS (Detai

CONCENTRATIONS AND RISKS (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Concentration Risk [Line Items]
Discounts and debt issuance cost	$ 73,500	$ 16,000
Proceeds from convertible debt	766,500	$ 325,000
Lenders [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt	$ 766,500
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender One [Member]
Concentration Risk [Line Items]
Concentration risk percentage	21%	39%
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender Two [Member]
Concentration Risk [Line Items]
Concentration risk percentage	47%	61%
Convertible Debt Benchmark [Member] | Lender Concentration Risk [Member] | Lender Three [Member]
Concentration Risk [Line Items]
Concentration risk percentage	32%
Accounts Receivable [Member] | Credit Concentration Risk [Member] | Receivable [Member]
Concentration Risk [Line Items]
Concentration risk percentage	100%
Lender One [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt	$ 160,000	$ 125,000
Lender Two [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt	360,000	$ 200,000
Lender Three [Member]
Concentration Risk [Line Items]
Proceeds from convertible debt	$ 246,500

SCHEDULE OF FAIR VALUE MEASUREM

SCHEDULE OF FAIR VALUE MEASUREMENTS, RECURRING AND NONRECURRING, VALUATION TECHNIQUES (Details) - Convertible Debt [Member]	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt instrument, measurement input, percentages	228	222
Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt instrument, measurement input, term	3 days	3 days
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt instrument, measurement input, percentages	1.28	0.05
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Debt instrument, measurement input, percentages	0	0

SCHEDULE OF FAIR VALUE, ASSETS

SCHEDULE OF FAIR VALUE, ASSETS AND LIABILITIES MEASURED ON RECURRING BASIS (Details) - USD ($)	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2020
Defined Benefit Plan Disclosure [Line Items]
Embedded conversion option liabilities	$ 151,262	$ 54,220
Embedded conversion option liabilities	151,262	54,220	$ 177,009
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Embedded conversion option liabilities
Embedded conversion option liabilities
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Embedded conversion option liabilities
Embedded conversion option liabilities
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Embedded conversion option liabilities	151,262	54,220
Embedded conversion option liabilities	$ 151,262	$ 54,220

SCHEDULE OF DERIVATIVE LIABILIT

SCHEDULE OF DERIVATIVE LIABILITIES AT FAIR VALUE (Details) - USD ($)	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Balance at Beginning	$ 54,220	$ 177,009
Gain on debt extinguishment	(2,069)	(130,975)
Change in fair value included in statements of operations	99,111	8,186
Balance at Ending	$ 151,262	$ 54,220

DERIVATIVE FINANCIAL INSTRUME_3

DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Details Narrative) - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Derivative Instruments, Gain (Loss) [Line Items]
Share price	$ 0.0037
Convertible Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Convertible debt	$ 79,000	$ 80,000

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative)															1 Months Ended								2 Months Ended	3 Months Ended	12 Months Ended
	Sep. 21, 2022 USD ($)	Aug. 15, 2022 USD ($)	Aug. 12, 2022 USD ($)	Aug. 02, 2022 USD ($) shares	Aug. 02, 2022 USD ($) shares	Jul. 27, 2022 USD ($)	Jul. 27, 2022 EUR (€)	Jul. 13, 2022 USD ($) $ / shares shares	Jul. 02, 2022 USD ($)	Jun. 30, 2022 USD ($) $ / shares shares	May 18, 2022 shares	May 12, 2022	Oct. 02, 2020 USD ($)	Oct. 02, 2020 EUR (€)	Jul. 31, 2023 USD ($)	Jul. 31, 2023 EUR (€)	Mar. 31, 2023 USD ($)	Mar. 31, 2023 EUR (€)	Dec. 31, 2022 USD ($)	Dec. 31, 2022 EUR (€)	Sep. 30, 2022 USD ($)	Sep. 30, 2022 EUR (€)	Sep. 14, 2022 USD ($) $ / shares shares	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2022 USD ($) $ / shares shares	Jun. 30, 2021 USD ($) $ / shares shares	Jun. 30, 2021 EUR (€) shares	Jun. 30, 2019 USD ($)	Jun. 30, 2019 EUR (€)	Nov. 30, 2020 USD ($)
Proceeds from the exercise of warrants																									$ 625,001	$ 776,044
Number of shares, exercised | shares
Common stock, shares issued | shares										220,350,921														220,350,921	220,350,921	14,055,393
Deemed dividend																									$ 700,340	$ 391,749
Issuance of common stock for cash, shares | shares											3,001,500,005														56,799,716
Debt instrument face amount										$ 1,000														$ 1,000	$ 1,000	95,000				$ 19,600
Interest payable										57,822														57,822	57,822	34,098				$ 416
Gross aggregate proceeds																								99,285	99,285
Debt instrument unamortized discount										31,669														31,669	$ 31,669	6,139
Lowest trading price percentage																									4.99%
Payment for services																										24,043	€ 28,493	$ 36,117	€ 31,754
University of Jaen [Member]
Payment for services													$ 30,268	€ 25,837
Securities Purchase Agreement [Member]
Debt instrument unamortized discount										452,308														452,308	$ 452,308	$ 498,160
Securities Purchase Agreement [Member] | 1800 Diagonal Lending LLC [Member] | July 11, 2022 1800 Diagonal Note [Member]
Debt instrument face amount										105,000														$ 105,000	$ 105,000
Debt issue costs										$ 3,750
Debt instrument debt default interest rate										35%
Debt instrument description										The conversion price for the above note shall be equal to a 35% discount of the market price which means the average of the lowest three trading prices of the Common Stock for the ten trading days immediately prior to the delivery of a Notice of Conversion. Notwithstanding the foregoing, 1800 Diagonal shall be restricted from effecting a conversion if such conversion, along with other shares of the Company’s common stock beneficially owned by 1800 Diagonal and its affiliates, exceeds 9.99% of the outstanding shares of the Company’s common stock. The Company treats this convertible note as stock settled debt under ASC 480.
Percentage of outstanding shares of common stock										9.99%
Debt default amount percentage										22%
Securities Purchase Agreement [Member] | 1800 Diagonal Lending LLC [Member] | July 11, 2022 1800 Diagonal Note [Member] | Minimum [Member]
Debt instrument debt default interest rate										110%
Securities Purchase Agreement [Member] | 1800 Diagonal Lending LLC [Member] | July 11, 2022 1800 Diagonal Note [Member] | Maximum [Member]
Debt instrument debt default interest rate										129%
Securities Purchase Agreement [Member] | 1800 Diagonal Lending LLC [Member] | June 30, 2023 1800 Diagonal Note [Member]
Debt instrument maturity date												Jun. 30, 2023
Debt instrument, interest rate, stated percentage										8%														8%	8%
Research Agreement [Member] | Installment 2 [Member] | Forecast [Member]
Payment for services																					$ 8,091	€ 8,000
Research Agreement [Member] | Installment 3 [Member] | Forecast [Member]
Payment for services																			$ 7,080	€ 7,000
Research Agreement [Member] | Installment 4 [Member] | Forecast [Member]
Payment for services																	$ 10,114	€ 10,000
Research Agreement [Member] | Installment 5 [Member] | Forecast [Member]
Payment for services															$ 10,114	€ 10,000
Common Stock [Member]
Common stock, shares issued | shares										15,625														15,625	15,625	29,820
Issuance of common stock for cash, shares | shares																								25,663,288	25,663,288	29,820	29,820
Share price | $ / shares										$ 0.01														$ 0.01	$ 0.01	$ 0.10
Subsequent Event [Member]
Proceeds from the exercise of warrants					$ 50,000
Issuance of common stock for cash, shares | shares								14,336,712															264,492,661
Conversion price | $ / shares																							$ 0.001
Debt instrument face amount																							$ 327,200
Interest payable																							22,330
Premiums to additional paid in capital																							$ 133,646
Share price | $ / shares								$ 0.002
Gross aggregate proceeds								$ 24,711
Subsequent Event [Member] | Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member]
Debt instrument face amount	$ 71,500		$ 93,000
Debt instrument maturity date	Mar. 21, 2023		Apr. 12, 2023
Debt instrument, interest rate, stated percentage	8%		8%
Debt instrument debt default interest rate	24%		24%
Percentage of outstanding shares of common stock	4.99%		4.99%
Debt instrument unamortized discount	$ 4,000		$ 5,000
Legal fees	$ 2,500		$ 3,000
Conversion price, description	The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. GS Capital is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Capital Note then outstanding into shares of the Company’s common stock (the “Common Stock”) at a price for each share of Common Stock (“Conversion Price”) of $0.002 per share (the “Fixed Price”). However, in the event the Company’s Common Stock trades below $0.0014 per share for more than five (5) consecutive trading days, then the Fixed Price shall be equal to $0.0009 per share.		The GS Capital Note is exchangeable for an equal aggregate principal amount of notes of different authorized denominations, as requested by GS Capital surrendering the same. GS Capital is entitled, at its option, at any time after cash payment, to convert all or any amount of the principal face amount of the GS Capital Note then outstanding into shares of the Company’s common stock at a price for each share of Common Stock (“Conversion Price”) of $0.0028 per share (the “Fixed Price”). However, in the event the Company’s common stock trades below $0.002 per share for more than five (5) consecutive trading days, then the Fixed Price shall be equal to $0.0013 per share.
Lowest trading price percentage	65%		65%
Debt principal increase percentage	20%		20%
Subsequent Event [Member] | Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | Minimum [Member]
Debt instrument debt default interest rate	110%		110%
Litigation penalty amount.	$ 250		$ 250
Subsequent Event [Member] | Securities Purchase Agreement [Member] | GS Capital Partners, LLC [Member] | Maximum [Member]
Debt instrument debt default interest rate	125%		130%
Litigation penalty amount.	$ 500		$ 500
Subsequent Event [Member] | Securities Purchase Agreement [Member] | ONE44 Capital LLC [Member]
Debt instrument face amount		$ 110,000
Debt instrument maturity date		Aug. 15, 2023
Debt instrument debt default interest rate		65%
Percentage of outstanding shares of common stock		4.99%
Debt default amount percentage		24%
Legal fees		$ 5,500
Debt principal increase percentage		20%
Debt conversion original debt		$ 10,000
Subsequent Event [Member] | Securities Purchase Agreement [Member] | ONE44 Capital LLC [Member] | Minimum [Member]
Debt instrument debt default interest rate		120%
Litigation penalty amount.		$ 250
Subsequent Event [Member] | Securities Purchase Agreement [Member] | ONE44 Capital LLC [Member] | Maximum [Member]
Debt instrument debt default interest rate		135%
Litigation penalty amount.		$ 500
Subsequent Event [Member] | Research Agreement [Member]
Payment for services						$ 53,806	€ 53,200
Subsequent Event [Member] | Research Agreement [Member] | Installment 1 [Member]
Payment for services						$ 18,407	€ 18,200
Subsequent Event [Member] | Research Agreement [Member] | University of Jaen [Member] | Revenue Benchmark [Member] | Revenue from Rights Concentration Risk [Member] | No Customer [Member]
Royalties percentage						2%	2%
Subsequent Event [Member] | Consulting Agreement [Member]
Monthly Fee									$ 50,000
Stock fee percentage									9.90%
Subsequent Event [Member] | Common Stock [Member]
Number of shares, exercised | shares				1,250
Subsequent Event [Member] | Warrant [Member]
Deemed dividend				$ 389,235
Subsequent Event [Member] | Series B Warrants [Member]
Number of shares, exercised | shares				1,250
Subsequent Event [Member] | 792 Series A Warrants [Member]
Common stock, shares issued | shares				158,399,208	158,399,208